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Abstract 
English abstract 
 
Gemcitabine (GEM) is currently the standard treatment for advanced pancreatic 
adenocarcinoma, one of the most aggressive human tumors, although it has a 
response rate of less than 20%. The purpose of this thesis was to improve GEM 
activity by addition of cannabinoids, a novel class of antitumor compounds. This 
work shows that GEM induces both CB1 and CB2 receptors by an NF-κB-dependent 
mechanism and that its association with cannabinoids synergistically inhibits 
pancreatic adenocarcinoma cell growth and increases reactive oxygen species (ROS) 
induced by single treatments. This effect is prevented by the radical scavenger N-
acetyl-L-cysteine and by the specific NF-κB inhibitor BAY 11-7085, demonstrating 
that the induction of ROS by GEM/cannabinoids and of NF-κB by GEM is required 
for the antiproliferative synergism. Neither apoptotic nor cytostatic mechanisms are 
responsible for the synergistic cell growth inhibition, which is strictly associated to 
the enhancement of endoplasmic reticulum stress and autophagic cell death. . 
Noteworthy, the antiproliferative synergism is stronger in GEM-resistant compared 
to GEM-sensitive pancreatic cancer cell lines and no synergism is observed in 
normal primary fibroblasts. The combined treatment strongly inhibits growth of 
human pancreatic tumor cells xenografted in nude mice without apparent toxic 
effects.  
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Abstract 
Italian abstract 
 
Gemcitabina (GEM) è attualmente il chemioterapico standard per il trattamento 
dell'adenocarcinoma pancreatico, anche se ha un tasso di risposta inferiore al 
20%. Lo scopo di questa tesi è stato quello di migliorare l'attività della GEM con 
l'aggiunta di cannabinoidi, una nuova classe di composti antitumorali. Questo lavoro 
mostra che GEM è in grado di indurre entrambi i recettori dei cannabinoidi CB1 e 
CB2 tramite un meccanismo NF-κB-dipendente e che la sua associazione coi 
cannabinoidi inibisce sinergisticamente la crescita di cellule di adenocarcinoma 
pancreatico aumentando le specie reattive dell’ossigeno (ROS) indotte dai singoli 
trattamenti. Questo effetto è inibito dall’antiossidante N-acetyl-L-cysteine e dallo 
specifico inibitore di NF-κB, BAY 11-7085, dimostrando che l’induzione di ROS 
dalla combinazione GEM/cannabinoidi e di NF-κB da GEM è richiesta per la 
sinergia antiproliferativa. Né meccanismi apoptotici né citostatici sono responsabili 
della inibizione sinergica della crescita cellulare, che risulta invece strettamente 
associata all’aumento di stress del reticolo  e alla morte cellulare autofagica. 
La sinergia antiproliferativa è più forte nelle linee cellulari di pancreas resistenti alla 
GEM rispetto a quelle più sensibili e nessuna sinergia si osserva nei fibroblasti 
primari normali. 
Il trattamento combinato inibisce fortemente la crescita di cellule tumorali di 
pancreas umane xenotrapiantate in topi nudi senza apparenti effetti tossici. 
.  
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Introduction 
Introduction 
 
Pancreas anatomy and physiology 
 
The pancreas, an organ of endodermal derivation, is the key regulator of protein and 
carbohydrate digestion and glucose homeostasis.  
The exocrine pancreas (80% of the tissue mass of the organ) is composed of a 
branching network of acinar and duct cells that produce and deliver digestive 
zymogens into the gastrointestinal tract. The acinar cells, which are organized in 
functional units along the duct network, synthesize and secrete zymogens into the 
ductal lumen in response to cues from the stomach and duodenum. Within the acinar 
units near the ducts are centroacinar cells.  
The endocrine pancreas, which regulates metabolism and glucose homeostasis 
through the secretion of hormones into the bloodstream, is composed of four 
specialized endocrine cell types gathered together into clusters called Islets of 
Langerhans.  
Mirroring the physiologic and cellular diversity of the pancreas is a spectrum of 
distinct pancreatic malignancies that possess histological and molecular features that 
recall the characteristics of the various normal cellular constituents. These multiple 
tumor types and hallmark features are summarized in Table 1. Pancreatic ductal 
adenocarcinoma (PDAC), whose nomenclature derives from its histological 
resemblance to ductal cells, is the most common pancreatic neoplasm and accounts 
for >85% of pancreatic tumor cases [2]. 
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Pancreatic neoplasm Histological features Common genetic 
alteration 
 
Ductal adenocarcinoma 
 
Ductal morphology; desmoplasia 
 
K-RAS, p16INK4a, 
TP53, SMAD4 
 
Variants of ductal adenocarcinoma 
a. Medullary carcinoma 
b. Colloid (mucinous 
noncystic) carcinoma 
 
 
Poorly differentiated; intratumoral 
lymphocytes 
Mucin pools 
 
hMLH1, hMSH2 
MUC2 
overexpression 
Acinar cell carcinoma 
 
Zymogen granules APC/β-catenin 
Pancreatoblastoma Squamoid nests, multilineage 
differentiation 
 
APC/β-catenin 
Solid pseudopapillary neoplasm “Pseudo” papillae, solid and cystic 
areas, 
hyaline globules 
 
APC/β-catenin;  
CD10 expression 
Serous cystadenoma Multilocular cysts; glycogen-rich 
epithelium 
 
VHL 
Pancreatic endocrine tumors Hormone production MEN1 
 
 
 
Table 1: pancreatic tumors and associated genetic alterations 
Pancreatic Adenocarcinoma 
 
Pancreatic adenocarcinoma (PDAC) is one of the most aggressive and devastating 
human malignancies with a death-to-incidence ratio of 0.99 [3]. Although it 
represents only 2-3% of all cancers [4], pancreatic adenocarcinoma is the 4th cause 
of death by cancer after lung, prostate (breast in women), and colorectal cancers 
since 1970s.  
PDAC is associated with only a few known demographic and environmental risk 
factors and a handful of autosomal dominant genetic conditions. Multiple studies 
have established advanced age, smoking, and long-standing chronic pancreatitis as 
clear risk factors; diabetes and obesity also appear to confer increased risk. Increased 
risk has also been documented in relatives of PDAC patients, and it is estimated that 
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10% of PDAC cases are associated with an inherited predisposition based on familial 
clustering [2]. 
 
Molecular genetics of PDAC 
 
Many advances have been made over the past 2 decades in the characterization of the 
molecular alterations that take place in pancreatic cancer.  
These may be classified as alterations in: 
• oncogenes, 
• tumor suppressor genes,  
• growth factors. 
 
Oncogenes 
Certain genes exhibit increased biologic activity as a result of mutation and are 
termed oncogenes. The oncogene most commonly detected in human cancers is the 
RAS gene. Not surprisingly, the RAS gene is also the most important oncogene 
identified to date in pancreatic cancer. It comprises 3 families, H-RAS, K-RAS, and 
N-RAS. Of these, the K-RAS family is responsible for almost all of the pancreatic 
cancer mutations, with mutations in the other families occurring only rarely. 
The gene encodes p21, a membrane-associated guanine nucleotide binding signal 
transduction protein that regulates many cellular functions, including cell growth, 
proliferation, and differentiation. Studies suggest that K-RAS, which is located on 
chromosome 12p13, is mutated in up to 95% of pancreatic adenocarcinomas. These 
mutations, thought to be an early event in the pathogenesis of pancreatic carcinoma, 
are point mutations. These mutations in the K-ras gene result in a constitutively 
active GDP-bound product that promotes increased signal transduction and 
uncontrolled growth [5]. 
 
Tumor suppressor genes 
Inactivation of this class of genes results in the elimination of vital negative 
regulators of cell proliferation allowing for uncontrolled growth. A growing number 
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of tumor suppressor genes have been identified in the pathogenesis of pancreatic 
cancer:  
• p53, 
• members of the INK4 family,  
• DPC4/SMAD4. 
The p53 tumor suppressor gene is located on chromosome 17p. It encodes a 53-kD 
nuclear phosphoprotein that acts as a transcription factor capable of modulating the 
expression of an array of genes involved in critical functions, including cell cycle 
regulation, arrest, apoptosis, differentiation, DNA surveillance, and repair.  
p53 is thought to be mutated in anywhere between 40% and 100% of cases and 
constitutes the most commonly mutated tumor suppressor gene in pancreatic cancer. 
 
The p16 tumor suppressor gene was the first member to be identified in the INK4 
family of cyclin-dependent kinase (CDK) inhibitors. It is located on chromosome 9p 
and has been implicated in a variety of tumors, including pancreatic cancer. The p16 
gene product normally binds to the cyclin CDK4 complex and prevents it from 
phosphorylating the retinoblastoma protein (RB). In its nonphosphorylated state, the 
RB protein arrests the cell cycle at the G1/S checkpoint. It does so by forming a 
complex with E2F and, by sequestering it, preventing it from acting as a transcription 
factor that allows for the progression of the cell cycle into the S phase. Loss of p16 
activity results in no inhibition at the level of the cyclin-CDK4 complex and allows 
for uncontrolled growth. Studies suggest that p16 activity is lost in about 40% of 
pancreatic cancers by homozygous deletion. 
 
Growth Factors 
Various growth factors and their receptors have been implicated as modifying the 
level of aggression of pancreatic cancer and influencing the clinical course of the 
disease.  
The FGF (fibroblast growth factors) family consists of 19 homologous polypeptide 
growth factors that participate in a host of essential cell functions, including cell 
differentiation during tissue repair, mitogenesis, and angiogenesis. FGF-1-5 and 7 
have been found to be overexpressed in certain human pancreatic cancer cell lines. 
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Furthermore, most human pancreatic cancers have been shown to overexpress one 
(FGFR-1β) of the high affinity transmembrane tyrosine kinase receptors that function 
as signal molecules to mediate the effects of FGF. Upon binding a ligand, the FGF 
receptor homo- and heterodimerizes. It then transphosphorylates tyrosine residues 
located on its intracellular domain, which allows for signal transmission via one of 
various cascades. These include the phosphatidyl-inositol-3 kinase, the ras, raf, and 
MAP kinases. Which one is employed depends on the cell type, the types of 
receptors in the heterodimer, and the nature of the ligand. 
Activated MAP kinases then translocate to the nucleus where they induce oncogenes 
such as fos and jun, leading to cell proliferation. Some studies have reported 
increased levels of FGFR as well as closely related receptors such as HER 2 and 
HER 3 in human pancreatic cancer [1, 6]. Furthermore, it is also known that several 
ligands for the FGF receptor such as EGF, tumor growth factor- β (TGF- β), and 
heparin binding EGF-like growth factor (HB-EGF) are also overexpressed in 
pancreatic cancer. It has been proposed that this receptor-ligand system plays a role 
in pancreatic carcinogenesis via autocrine and paracrine mechanisms. 
Other growth factors that may play a role in pancreatic cancer include insulin-like 
growth factor (IGF), platelet-derived growth factor (PDGF), vascular endothelial 
growth factor (VEGF), and hepatocyte growth factor (HGF) [5]. 
 
Chemotherapy approach
 
Up to now, despite decades of efforts at elucidating molecular pathways involved in 
initiation and progression and at identifying effective therapies, the prognosis of 
pancreatic adenocarcinoma has not improved. At diagnosis, less than 20% of patients 
are candidates for surgery with curative intent [7].  
Standard treatments for advanced disease and for adjuvant and neo-adjuvant 
regimens include radiotherapy and/or chemotherapy. Radiotherapy has been shown 
to have some utility for regional confined cancers, but is often too toxic for tissues 
surrounding the neoplasia. Monotherapy with gemcitabine (GEM) has been the 
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standard treatment during the last decade, although it has a response rate of less than 
20% [8]. 
The cytosine analogue Gemcitabine (2’,2’-difluorudeoxycytidine, dFdC; GEM) is an 
S-phase nucleoside that is currently considered to be the single agent of choice in 
advanced pancreatic cancer. 
 
 
Figure 1: structure of GEM 
 
 
 
 
 
 
 
 
 
GEM (Figure 1) has three mechanisms of action: 
 
1. competes for incorporation into DNA, thereby inhibiting the synthesis of 
DNA;  
2. prevents DNA repair by masked termination;  
3. undergoes self-potentiation. 
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Figure 2: mode of action of GEM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GEM undergoes phosphorylation by deoxycytidine kinase to difluorodeoxycytidine 
di- then tri-phosphate. GEM diphosphate inhibits ribonucleotide reductase, which is 
the primary enzyme involved in the formation of deoxycytidine monophosphate, a 
natural substrate in DNA replication. This allows the incorporation of gemcitabine 
triphosphate nucleotides into the DNA chain during replication.  
GEM permits one more nucleotide to pair before termination of the replication 
process. This means that the GEM nucleotide is less susceptible to excision repair by 
exonuclease enzymes, making DNA repair more difficult (masked termination).  
GEM also perpetuates its own activity and survival by reducing deoxycytidine 
triphosphate inhibition of deoxycytidine kinase (which phosphorylates GEM) and 
inhibiting deoxycytidine monophosphate deaminase (normally integral in GEM 
degradation). Deoxycytidine monophosphate deaminase is inhibited directly by GEM 
triphosphate and indirectly inhibited by GEM diphosphate.  
GEM has shown a 5–11% response rate for advanced pancreatic cancer, with a 
median survival rate of 5.7–6.3 months in Phase I and II studies. In the pivotal Phase 
III trial the median survival was increased from 4.4 months using bolus i.v. 5-FU (63 
patients) to 5.7 months with GEM (63 patients), and the one-year survival was 
increased from 2% to 18%, respectively [9]. 
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Many clinical trials have failed to demonstrate an improvement in overall survival 
(OS) with the addition of different drugs to GEM, including cetuximab and 
bevacizumab. Nevertheless, some modest but interesting advances have been 
provided by drug combination therapies such as GEM-erlotinib, GEM-capecitabine, 
and GEM plus a platinum salt [7]. Nowadays, research is focused on the 
identification of other potential targets of response, the regulation of which may 
improve GEM antitumoral activity, which does provide a modest improvement in the 
quality of life [8]. 
 
Reactive oxygen species 
 
Reactive oxygen species (ROS) are chemically-reactive molecules containing 
oxygen. Examples include free radicals such as superoxide (O2· -), hydroxyl radical 
(OH·), and non-radical molecules, such as hydrogen peroxide (H2O2).  
Various pathways of ROS formation exist. The production of superoxide occurs 
mostly within the mitochondria of a cell. The mitochondrial electron transport chain 
is the main source of ATP in the mammalian cell and thus is essential for life. During 
energy transduction, a small number of electrons “leak” to oxygen prematurely, 
forming the oxygen free radical superoxide. Mitochondria, in fact, are considered the 
major source of cellular production of ROS: it is estimated that 2% of consumed 
oxygen reacts with electrons that escape from the respiratory chain, produces 
superoxide ion, and is then converted into hydrogen peroxide. An excess of ROS 
causes oxidative stress that leads to the activation of many cellular antioxidant 
systems (eg. superoxide dismutase, catalase, glutathione system, thioredoxin) in 
order to avoid damage to DNA, proteins and lipids [10]. 
The ROS production correlates with normal cell proliferation through activation of 
growth-related signalling pathways. Indeed, exposure to low levels of ROS can 
increase growth of many types of mammalian cells, whereas scavengers of ROS 
suppress normal cell proliferation in human and rodent fibroblasts.  
Furthermore, growth factors trigger hydrogen peroxide (H2O2) production that leads 
to mitogen-activated protein kinase activation and DNA synthesis, a phenomenon 
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inhibited by antioxidant molecules. Several observations suggest that ROS also 
participate in carcinogenesis: 
1. ROS production is increased in cancer cells and an oxidative stress can 
induce DNA damages that lead to genomic instability and possibly stimulate 
cancer progression; 
2. elevated ROS levels are responsible for constant activation of transcription 
factors, during tumor progression. 
Whereas, under certain circumstances, ROS promote cell proliferation, they can also 
induce apoptosis. Indeed, most anticancer drugs kill their target cells at least in part 
through the generation of elevated amounts of intracellular ROS. ROS can stimulate 
proapoptotic signal molecules, such as apoptosis signal regulating kinase 1, c-Jun-
NH2-kinase, and p38; activate the p53 protein pathway; or engage the mitochondrial 
apoptotic cascade. The various ROS can exert different effects according to their 
nature and to their intracellular level, which is determined by both their production 
rate and the activity of antioxidant enzymes. 
More recent studies have shown that cancer cells have a level of ROS higher than 
normal cells, associated with oncogenic stimulation, alterations in metabolic and 
mitochondrial malfunction. The consequences of increased oxidative stress are the 
stimulation of proliferation, the increase in mutations and genetic instability [1]. The 
intrinsic oxidative stress of cancer cells is a feature that can be exploited 
therapeutically. Because cancer cells produce high levels of ROS and are under 
increased oxidative stress, it is reasonable to speculate that compared to normal cells, 
the malignant cells would be more dependent on antioxidant enzymes and other 
antioxidant defense systems to cope with such stress. It follows that inhibition of 
antioxidant enzymes or exposure to further exogenous ROS insults would cause 
more ROS-mediated damage in cancer cells than in normal cells [6]. This model was 
also confirmed by our group on pancreatic adenocarcinoma cells and normal human 
fibroblasts following treatment with the oxidant DEM (DiEthyl Maleate), a known 
oxidant agent). DEM inhibited the growth of adenocarcinoma cell lines in a dose 
dependent manner, while it was ineffective on normal human fibroblasts. 
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Figure 3: model proposed to explain the opposite effects of various concentrations of 
intracellular H2O2 on cellular proliferation of nontransformed and tumor cells [1]. 
 
Gemcitabine and ROS 
 
Recently, our research group showed that GEM induces an approximately 2-fold 
increase of intracellular free radicals and that 1 mM of the radical scavenger NAC 
(N-acetyl-L-cysteine) is able to rescue, at least in part, the antiproliferative effect of 
GEM. Moreover, a positive correlation was found between the intrinsic ROS stress 
and the sensitivity to GEM in 10 pancreatic adenocarcinoma cell lines (Table 2 and 
Fig 4) [11, 12]. 
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Cell lines Origin IC50 GEM (nM) 48h RMF 
PSN1 Primary 8 30.2 
PC1J Primary 30 31 
PT45P1 Primary 50 60.9 
MiaPaCa2 Primary 90 50.8 
PaCa3 Primary 220 4.7 
PaCa44 Primary 250 3.2 
Panc1 Primary 200 2.4 
CFPAC1 Metastasis (liver) 9.5 57.1 
T3M4 Metastasis (node) 25 48.6 
HPAFII Metastasis (ascites) 40 35.4 
 
 
 
 
Table 2: IC50 value of 48h GEM and relative mean fluorescence (RMF) of pancreatic 
adenocarcinoma cell lines. Relative mean fluorescence is the ratio between fluorescence 
intensity of cells treated and untreated (autofluorescence) with 2’,7’-dichlorofluorescein 
(DCF) and correspond to the basal level of ROS. 
 
 
Figure 4: RMF versus IC50. 
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The different levels of ROS in normal and tumor cells may allow a selective action 
of chemotherapy to the cancer cells. This effect might be achieved by combining 
GEM with one or more oxidizing agents to further increase intracellular oxidative 
stress of cancer cells. 
 
Cannabinoids 
 
Cannabis has been used for many years and for many different purposes (i.e. fiber, 
medicinal, ...). However, the endocannabinoid signaling system has only recently 
been the focus of medical research and considered a potential therapeutic target [13]. 
At the present time, three general types of cannabinoids have been described :  
• phytocannabinoids occur uniquely in the cannabis plant;  
• endogenous cannabinoids are produced in the bodies of humans and 
other animals;  
• synthetic cannabinoids are similar compounds produced in a laboratory. 
 
Phytocannabinoids, also called natural cannabinoids, herbal cannabinoids, and 
classical cannabinoids, are only known to occur naturally in significant quantity in 
the cannabis plant, and are concentrated in a viscous resin that is produced in 
glandular structures known as trichomes. In addition to cannabinoids, the resin is rich 
in terpenes, which are largely responsible for the odour of the cannabis plant. 
Phytocannabinoids are nearly insoluble in water but are soluble in lipids, alcohols, 
and other non-polar organic solvents. However, as phenols, they form more water-
soluble phenolate salts under strongly alkaline conditions. 
All natural cannabinoids are derived from their respective 2-carboxylic acids (2-
COOH) by decarboxylation (catalyzed by heat, light, or alkaline conditions). 
At least 70 cannabinoids have been isolated from the cannabis plant. 
Tetrahydrocannabinol (THC), cannabidiol (CBD) and cannabinol (CBN) are the 
most prevalent natural cannabinoids and have received the most study.   
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Endocannabinoids mimic the pharmacological actions of the psychoactive principle 
of marijuana, Δ9 tetrahydrocannabinol (Δ9-THC). Endocannabinoids are endogenous 
lipid signaling molecules. They are generated in the cell membrane from 
phospholipid precursors and possess cannabimimetic properties because they bind 
and activate one or more cannabinoid receptor subtypes. Endocannabinoids are 
implicated in different physiological and pathological functions (regulation of food 
intake, immunomodulation, inflammation, analgesia, cancer, addictive behavior, 
epilepsy and others). The two best-studied endocannabinoids isolated to date are 
arachidonoylethanolamine (anandamide or AEA) and 2-arachidonoylglycerol (2-
AG). AEA is hydrolyzed by the enzyme fatty-acid amide hydrolase (FAAH) whereas 
2-AG is degraded by the enzyme monoacylglycerol lipase (MGL).  
 
Synthetic cannabinoids are particularly useful in experiments to determine the 
relationship between the structure and activity of cannabinoid compounds, by 
making systematic, incremental modifications of cannabinoid molecules. Laboratory 
synthesis of cannabinoids was often based on the structure of herbal cannabinoids, 
and a large number of analogues have been produced and tested. 
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Figure 5: types of cannabinoids. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cannabinoid receptors 
 
Cannabinoids produce their effects through the activation of distinct G protein-
coupled receptors identified as the cannabinoid CB1 and CB2 receptors. These are 
members of the superfamily of seven-transmembrane-spanning G protein-coupled 
receptors and share 44% identity at the protein level. Similarity increases to 68% 
when only the transmembrane region is considered. Activation of both cannabinoid 
receptor subtypes inhibits adenylate cyclase activity by coupling to the α–subunit of 
the G protein of the Gi/o family (Gi 1, 2 and 3, and Go 1 and 2). 
In contrast to CB2 receptor activation, CB1 receptor activation modulates calcium or 
potassium conductance, property linked to the suppression of neuronal excitability 
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and neurotransmitter release. However, activation of MAPK and Krox-24 expression 
presumably through the activation of G-protein βγ subunits is another signalling 
mechanism recruited by both CB1 and CB2 receptors. Furthermore, CB1 receptor 
activation can inhibit type 5-HT3 ion channels, modulate the production of nitric 
oxide, alter sodium channel conductance and activate the Na+/H+ exchanger [13]. 
 
The CB1 receptor was first cloned in 1990 from a cortical rat brain cDNA library, 
this was followed by the cloning of human and mouse analogues. These encode 
proteins of 427 (human) and 473 (rat) amino acids and have 97–99% amino acid 
sequence homology across species [14]. CB1 receptors are found mainly in the CNS 
and, to a lesser extent, in certain peripheral tissues. At the peripheral level, they are 
localized in adrenal gland, adipose tissue, heart, liver, lung, prostate, uterus, ovary, 
testis, bone marrow, thymus, tonsils and presynaptic nerve terminals. Within the 
brain, they are found in the cerebral cortex, hippocampus (with highest 
concentrations in the dentate gyrus), amygdala, basal ganglia, substantia nigra pars 
reticulata, internal and external segment of the globus pallidus and cerebellum 
(molecular layer). The distribution of cannabinoid receptors provides an anatomical 
basis for the analgesic effects of the cannabinoids. Activation of presynaptic CB1 
receptors in different brain regions or on primary afferents inhibits the release of 
neurotransmitters by decreasing calcium conductance and by increasing the 
potassium conductance [13]. 
 
CB2 receptors are primarily localized to cells of the immune system. The CB2 
receptor was cloned in 1993 from human promyelocitic HL-60 cells. This gene 
encodes a protein of 360 amino acids, and is only 48% homologous to CB1 [14]. 
CB2 receptors are mainly found in the spleen, tonsils and thymus, tissues responsible 
for immune cell production and regulation. These immune cells include mast cells, B 
cells, T4 and T8 cells, microglial cells, macrophages, natural killer cells and, to a 
lesser extent, monocytes and polymorphonuclear neutrophils. Previous reports 
suggested that CB2 receptors were absent in neurons of the central nervous system 
(CNS). However, recent studies suggest that they are found in the brain, on dorsal 
 19
Introduction 
root ganglia, in the lumbar spinal cord, on sensory neurons, on microglia as well as 
in peripheral tissues. 
A better understanding of the role of cannabinoid receptors in different physiological 
processes has been obtained through research employing pharmacological and 
genetic tools such  knockout mice with disrupted CB1 and/or CB2 genes [13]. The 
role of the CB1 receptor in the central effect of cannabinoids was investigated by 
measuring the response of  CB1+/+ and CB1-/- mice  to THC in different assay. These 
experiment have shown that the main pharmacological effect of THC are mediated 
by the CB1 receptor [15]. The same experiment was performed for tested if the 
immune effects are mediated by cannabinoid CB2 receptors. Were evaluated the 
immunomodulatory effects of cannabinoids in cannabinoid CB2 receptor deficient 
mice using a T cell co-stimulation assay. THC inhibits helper T cell activation 
through macrophages derived from wild type, but not from knockout mice, thus 
indicating that this effect is mediated by the cannabinoid CB2 receptor [16]. 
 
 
Figure 6: structure of cannabinoid receptors 
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Antitumoral action of cannabinoids 
 
Cannabinoids have been successfully used in the treatment of some of the side 
effects, such as nausea and vomiting, weight loss, lack of appetite and pain that often 
accompany cancer. Δ9-THC (Dronabinol) and LY109514 (Nabilone) are approved to 
treat nausea and vomiting associated with cancer chemotherapy. Although 
cannabinoids are used in the palliative treatment of cancer, they are not yet used as a 
treatment for tumor progression itself. However, the first study to show that 
cannabinoids had anti-tumor effects was reported by Munson et al. in 1975. They 
demonstrated that administration of Δ9-THC, Δ8-THC and cannabinol inhibited the 
growth of Lewis lung adenocarcinoma cell growth in vitro, and in vivo after oral 
administration to mice. Since then, cannabinoids have been shown to have anti-
proliferative, anti-metastatic, anti-angiogenic and pro-apoptotic effects in various 
cancer types (lung, glioma, thyroid, lymphoma, skin, pancreas, uterus, breast and 
prostate carcinoma) using both in vitro and in vivo models. Recently, more evidence 
has been obtained that suggests that phyto, endo- and synthetic cannabinoids could 
be useful in the treatment of cancer due to their ability to regulate cellular signalling 
pathways critical for cell growth and survival [14]. 
Recent findings have also shown that the ER stress–evoked upregulation of the 
p8/TRB3 pathway induced autophagy via inhibition of the Akt/mTORC1 axis and 
that activation of autophagy promoted the apoptotic death of tumor cells [17]. 
The majority of the literature demonstrates that various cannabinoids inhibit cancer 
cell growth in vitro and tumor growth in vivo and that the induction of apoptosis 
plays a major role in the mechanism for this effect. The potency of this effect varies 
with each cannabinoid. Therefore, the differences in binding properties at the 
cannabinoid receptors may result in different downstream effects. For example, 
partial agonism at the cannabinoid receptors by Δ9-THC or AEA compared to potent 
full agonism at the cannabinoid receptors by the synthetic cannabinoids JWH-133 or 
WIN 55,212-2, could lead to a divergence of downstream signaling that could 
produce altered responses in cell growth. The full potential of these synthetic 
cannabinoids has yet to be determined and there is a need for much more extensive 
research into the dose-response relationships as well as the mechanisms elicited by 
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the specific cannabinoids if cannabinoids are going to be further developed into 
potential cancer treatments [14]. 
 
Autophagy 
 
During the genesis of cancer, tumour cells experience various forms of intracellular 
and extracellular stress. This hostile situation results in damage to cellular proteins, 
the production of reactive oxygen species (ROS) and the replication of cells with 
heritable DNA damage. Tumour cells must therefore utilise homeostatic mechanisms 
in order to maintain sufficient energy and integrity in order to survive. 
Macroautophagy (hereafter referred to autophagy for simplicity) is one process 
within the cell that can serve to support these demands, through the lysosomal-
mediated degradation of cellular proteins and organelles. This not only results in the 
removal of damaged cellular constituents, but also, where required, can provide the 
catabolic intermediates for intracellular production of ATP when exogenous energy 
supplies are limited. 
However, although a clear role in cell survival undoubtedly exists, evidence also 
points to a tumour-suppressive role: downregulation of several autophagy genes 
occurs in human cancer, mouse models where critical autophagy regulators have 
been deleted support a role for autophagy in tumour suppression, and autophagy has 
been implicated in cell death and oncogene-induced senescence.  
Autophagy when translated from the Greek, that literally means ‘self-eating’, 
comprises a multistep process of sequestration and subsequent degradation of 
intracellular material within specialised compartments. 
Autophagy is orchestrated by a subset of genes that were originally identified in 
yeast and are called autophagy-related genes (ATG), many of which have 
mammalian orthologues [18]. 
 
 
Autophagy can be divided into different stages: 
1. initiation; 
2. autophagosome formation (nucleation, elongation and completion); 
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3. maturation; 
4. degradation. 
 
Figure 7: autophagy stages 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initiation 
 
Initiation in mammalian cells starts with the activation of a serine/threonine kinase 
complex that contains ULK1/2 (orthologues of the yeast protein Atg1), ATG13 and 
FIP200. This complex transfers signals from the nutrient-sensing mTOR kinase 
(MTOR; mammalian/mechanistic target of rapamycin) to initiate autophagy. 
Inhibition of mTOR-induced phosphorylation of ULK and ATG13 liberates the 
kinase activity of ULK, which subsequently phosphorylates itself, ATG13 and 
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FIP200. The ULK complex then accumulates at the initiating focus of vesicle 
formation: the isolation membrane or phagophore [18]. 
 
Autophagosome formation 
 
Vesicle nucleation depends on the activity of the class III phosphoinositide 3-kinase 
(PI3K-III), hVps34 (the orthologue of yeast Vps34) and its formation of a complex 
with Beclin 1 (yeast Atg6) and p150/hVps35 [19, 20]. Vesicle elongation and 
completion from the isolation membrane/phagophore to a nascent autophagosome 
and the completed, closed autophagosome is mediated by two ubiquitin like 
conjugation systems: the ATG12 and ATG8 conjugation systems [18]. The ubiquitin-
like ATG12 is activated by ATG7 and then temporarily binds to the E2-like enzyme 
ATG10 before being transferred to ATG5. ATG5 further reacts with ATG16 to form 
a multimeric complex of ATG12–ATG5–ATG16 [21, 22].  
LC3 is synthesised as a precursor protein proLC3 and is immediately processed to 
LC3-I by ATG4 through cleavage of the C-terminal amino acid. LC3 maturation 
completes with the reversible conjugation of LC3-I to phosphatidylethanolamine 
(PE) at the C-terminus by ATG3 and ATG7 to form LC3-II on the surface of 
autophagosomes [21, 22].  
Both the ATG12–ATG5–ATG16 complex and LC3-II are essential for autophagy. 
The ATG12–ATG5–ATG16 complex is required for targeting of LC3 to the 
autophagosomal membrane and accelerated conjugation of LC3 to PE. 
 
Maturation and degradation 
 
The maturation process encompasses the fusion of autophagosomes with lysosomes 
to form the end-stage vesicle of autophagy: the autolysosome. 
Molecular mechanisms of autophagosome maturation are only recently emerging and 
involve the actions of lysosomal proteins LAMP1 and LAMP2, the small GTPase 
Rab7 (RAB7A) and UVRAG (the protein product of the ultraviolet-radiation-
resistance-associated gene) [23]. The tumour suppressor UVRAG not only regulates 
the interaction of Beclin 1 and hVps34 at the stage of vesicle nucleation but also 
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plays an important role in the maturation step. UVRAG directs so-called tethering 
proteins (i.e. proteins that connect the autophagosome to its target) to the 
autophagosomal membrane and thereby activates Rab7 to facilitate fusion with 
lysosomes [19]. The final autolysosome is an acidic vesicle wherein the intracellular 
material gets degraded by lysosomal hydrolases, especially cathepsins. 
Amino acids and other constituent parts generated in this catabolic process are then 
released from the autolysosome to fuel cellular resources.  
 
ER-stress 
 
The endoplasmic reticulum (ER) is an organelle with crucial biosynthetic and 
signaling functions in eukaryotic cells. The ER is not only the major intracellular 
calcium (Ca2+) storage organelle critically involved in Ca2+ homeostasis and Ca2+ 
mediated signaling pathways, but it also provides the environment for the synthesis, 
folding, and modification of proteins destined to be secreted or embedded in the 
plasma membrane. Moreover, the ER is the major site for the biosynthesis of 
steroids, cholesterol, and lipids. Proper folding, maturation, and stabilization of the 
nascent protein in the ER require the highly oxidizing and Ca2+-rich ER environment, 
which is essential for the different post translational and cotranslational 
modifications, including glycosylation and disulfide bridge formation, to which 
proteins are subjected after entering the ER. These processes are assisted and 
monitored by several resident chaperones and Ca2+ binding proteins, including the 
glucose-regulated proteins such as GRP78, BiP, calreticulin and calnexin, and 
several folding enzymes, such as the thioredoxin-like protein disulfide isomerase 
(PDI). 
Proteins that fail to adopt a correctly folded or native conformation, or a proper 
oligomeric assembly in case of multisubunit proteins, are retrotranslocated to the 
cytosol through a process known as ER-associated protein degradation (ERAD), and 
further degraded by the 26S proteasome. 
The term ‘endoplasmic reticulum stress’ defines any perturbation that compromises 
the protein folding functionality of the ER [24]. 
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The ER-stress response is generally activated in response to various stressful 
conditions, such as hypoxia, low glucose levels, alterations of calcium homeostasis, 
the accumulation of misfolded proteins, and others. Several of these conditions are 
particularly relevant in tumor cells. For instance, the vigorous growth of tumors may 
expose cells at the frontline of expansion to regions with insufficient blood supply 
and therefore low oxygen and glucose availability. The latter condition is further 
exacerbated by the general metabolic phenotype of tumor cells that shifts the 
emphasis of sugar breakdown from oxidative phosphorylation to ‘‘aerobic 
glycolysis” (Warburg effect), necessitating the increase of sugar consumption. In 
addition, highly proliferative growth, in particular when combined with a secretory 
phenotype such as is present in multiple myeloma or prostate carcinoma cells, 
requires revved up protein synthesis and therefore leads to the accumulation of 
misfolded, damaged, and other garbage proteins as byproducts . As illustrated in Fig. 
6, all of these conditions are known to trigger the ER-stress response (also called the 
unfolded protein response, UPR, when the causative trigger relates to 
misfolded/unfolded proteins) [25]. 
 
 
Figure 8: Simplified description of the ER stress. 
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The initial effort of the ER-stress response is to protect the stressed cells by 
reestablishing homeostasis or otherwise neutralize the damaging consequences of the 
insult. One of the critical players in this process is GRP78 (glucose regulated protein 
of molecular weight 78), a calcium-binding protein that is primarily located in the 
ER lumen. It functions as a major chaperone during protein folding and also controls 
the activity of three major signaling pathways that originate from three different ER 
transmembrane proteins: 
• IRE1α 
• PERK 
• ATF6 
The lumenal domains of all of these proteins bind to the GRP78. 
Inositol requiring enzyme 1a (IRE1α), which is conserved across eukaryotic species, 
contains a lumenal stress sensing domain and a cytosolic protein kinase domain. It is 
thought that IRE1α is activated by dimerization, which leads to trans-
autophosphorylation and activation of a cytosolic endoribonuclease activity. To date, 
the only known substrate of the IRE1α endoribonuclease is X-box binding protein 1 
(Xbp1) mRNA, from which a 26 base intron is removed by IRE1α. This splicing  
event alters the Xbp1 translational reading frame to fuse a C-terminal transactivation 
domain to the N-terminal DNA binding domain. The pancreatic ER eIF2α kinase 
(PERK) protein, which consists of a lumenal domain homologous to IRE1α and an 
unrelated cytosolic Ser/Thr kinase domain, similarly dimerizes or oligomerizes 
during ER stress. Its autophosphorylation directs PERK activity toward the subunit 
of the eukaryotic initiation factor 2 (eIF2) translation initiation complex. eIF2a 
phosphorylation inhibits delivery of the initiator methionyl-tRNAi to the ribosome 
and ultimately results in a general inhibition of protein translation. Finally, the 
activating transcription factor 6 (ATF6) protein is activated when ER stress liberates 
the molecule for transit from the ER to the Golgi, where regulated intramembrane 
proteolysis by site-1 protease and site-2 protease releases a cytosolic fragment that is 
a transcriptional coactivator. Based on the fact that IRE1α, PERK and ATF6 are 
freed from GRP78 during ER stress, GRP78 binding seems important in regulating, 
either directly or indirectly, activation of each arm of the UPR [24]. 
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While GRP78 is difficult to detect in normal cells and generally requires their prior 
experimental exposure to ER-stress inducing agents, many tumor cell lines and 
primary clinical samples display permanently elevated levels of GRP78. This latter 
phenotype not only reflects these cells continuously ongoing effort to neutralize the 
potentially harmful effects of chronic stress within the tumor, but may also be an 
expression of permanent changes in cancer cell metabolism, such as Warburg effect. 
Unfortunately, because GRP78 also functions to suppress pro-apoptotic pathways, its 
elevated presence in tumor cells supports chemoresistance and thereby may worsen 
prognosis. 
The protective effort of the ER-stress response does not have unlimited capacity. 
When ER stress becomes too severe, this system will turn on its pro-apoptotic 
program, which will trigger cell death despite the presence of high levels of GRP78. 
One of the decisive effectors of this switch is CHOP (CCAAT/enhancer binding 
protein homologous transcription factor). Increased levels of CHOP, a transcription 
factor, alters the transcriptional profile and facilitates a pro-apoptotic program that 
involves suppression of Bcl-2, stimulation of death receptor 5 (DR5), activation of 
caspases, and mitochondrial events that function to integrate and amplify the death 
pathway. In normal cells, CHOP is expressed at negligible levels. Similarly, tumor 
cells display insignificant amounts of CHOP, despite chronic ER stress, because 
elevated levels of GRP78 suppress those signaling pathways that are able to activate 
CHOP transcription (Fig. 9). In response to acutely increased ER stress, however, 
both normal and tumor cells stimulate CHOP expression, and the duration and 
amount of elevated CHOP levels are a decisive factor in determining the cell’s fate. 
In case the protective components are able to regain control and subdue CHOP 
expression, the cell will survive. However, if severe ER stress persists, the pro-
apoptotic program will attain dominance and will initiate cell death. Because of their 
relatively short-lived struggle for control, CHOP expression levels can be used as a 
convenient readout to reveal the acute phase of ER stress [25]. 
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Figure 9: Differential ER stress levels, relating to normal cells (left panel), tumor cells or 
moderately stressed normal cells (middle panel), and moderately aggravated tumor cells or 
severely stressed normal cells (right panel). 
 
Autophagy and ER-stress 
 
The ER stress response is activated to protect the cells from different alterations 
affecting this organelle. However, when the intensity or duration of the ER damage 
cannot be restored by this response, ER stress can also lead to cell death. Likewise, 
autophagy can help cells to cope with ER stress (for instance contributing to the 
elimination of unfolded or aggregated proteins) or participate in the mechanism of 
ER stress induced cell death. 
Evidence for a link between UPR and autophagy was obtained from ectopic 
expression of polyglutamine (polyQ) proteins. In these experiments, a dominant-
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negative form of PERK or genetic substitution of Serine 51 of eIF2α by Ala (which 
prevents the phosphorylation of this protein) prevented polyQ protein [26] induced 
autophagy, strongly suggesting that PERKdependent eIF2α phosphorylation plays an 
important role in the activation of autophagy in response to the accumulation of 
unfolded proteins. On the other hand, eIF2α phosphorylation seems to be also 
important for autophagy as induced by other ER stress-related or unrelated stimuli 
[17, 27, 28]. It is important to bear in mind that PERK is not the only protein kinase 
regulating eIF2α phosphorylation, in fact  PERK-eIF2α-dependent Atg12 
upregulation is required for induction of autophagy in response to polyQ protein 
accumulation which suggests that controlling the expression of autophagy-related 
genes by eIF2α downstream targets could be one of the mechanisms connecting both 
events. In any case, further research is still necessary to clarify the precise 
mechanisms by which eIF2α phosphorylation regulates autophagy in response to 
different ER stress signals. 
Activation of the IRE1 arm of the ER stress response has also been shown to regulate 
autophagy. Thus, treatment with tunicamycin or thapsigargin [29] or treatment with 
proteasome inhibitors [30] induced autophagy on an IRE1- dependent manner. The 
proautophagic actions of IRE1 seem to rely on the ability of this protein to interact 
with the cytosolic adaptor TRAF-2 and activate JNK [29]. Of interest, JNK has been 
proposed to regulate autophagy through Bcl-2 phosphorylation, which prevents this 
protein of interacting (and inhibiting) the essential autophagy regulator Beclin-1 [31, 
32]. In addition, JNK has been shown to control Beclin-1 expression to regulate 
ceramide-induced autophagy. As discussed above, Beclin-1 is associated to the 
Vps34 and plays a very important role in the regulation of autophagy [33]. It is 
therefore conceivable that activation of the IRE1/TRAF2/JNK arm of ER stress may 
regulate autophagy through modulation of Beclin-1 function and expression. 
Intriguingly, it has been recently shown that XBP-1 ablation increases autophagy and 
protects from the toxicity induced by the aggregates of the enzyme superoxide 
dismutase 1 in a model of Amyotrophic lateral sclerosis [34]. These observations 
suggest that the XBP-1 may play a different role than TRAF2/JNK on the regulation 
of autophagy by the Ire1 arm of the UPR. 
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Purpose of the thesis 
 
Pancreatic adenocarcinoma (PDAC) is one of the most aggressive and devastating 
human malignancies with a death-to-incidence ratio of 0.99 [3]. Although it 
represents only 2-3% of all cancers [4], pancreatic adenocarcinoma is the 4th cause 
of death by cancer after lung, prostate (breast in women), and colorectal cancers 
since 1970s.  
Up to now, despite decades of efforts at elucidating molecular pathways involved in 
initiation and progression and at identifying effective therapies, the prognosis of 
pancreatic adenocarcinoma has not improved. At diagnosis, less than 20% of patients 
are candidates for surgery with curative intent [7].  
Monotherapy with gemcitabine (GEM) has been the standard treatment during the 
last decade, although it has a response rate of less than 20% [8]. Then is very 
important to identify new molecules acting in synergy with the GEM. 
Cannabinoids have been shown to have anti-proliferative, anti-metastatic, anti-
angiogenic and pro-apoptotic effects in various cancer types (lung, glioma, thyroid, 
lymphoma, skin, pancreas, uterus, breast and prostate carcinoma) using both in vitro 
and in vivo models [14]. Since the cannabinoids are well tolerated by the body, 
their use in combination with GEM could be a new way to treat pancreatic 
adenocarcinoma. 
The purpose of this thesis was to analyse the antiproliferative effects determined by 
addition of cannabinoids to GEM both in vitro and in vivo and to 
study some molecular mechanisms associated with them. 
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Materials and methods 
 
Chemicals 
 
Gemcitabine (2,2-difluorodeoxycytidine; GEM, Gemzar, Lilly) and N-acetyl-L-
cysteine (NAC) were freshly prepared in sterile water.  
 
Arachidonoyl cyclopropamide (ACPA) was obtained from Cayman Chemicals 
(Inalco) already solubilised in ethanol and stored at −20 °C until use. 
 
GW405833 hydrochloride [1-(2,3-dichlorobenzoyl)-2-methyl-3-(2-[1-morpholine] 
ethyl)-5-methoxyindole] was obtained from Sigma, solubilised in DMSO and stored 
at 4°C. 
  
SR141716 (N-(piperidino-1-yl)-5-(4-chlorophenyl)-1-(2,4dichlorophenyl)-4-methyl-
pyrazole-3-carboxamide; rimonabant; Acomplia®, Sanofi-Aventis) was kindly 
provided by Dr. Maurizio Bifulco (University of Naples, Italy), solubilised in DMSO 
and stored at −20°C until use.  
 
E64d (Sigma) and pepstatin A (AppliChem) were solubilised in sterile water and 
ethanol, respectively, and stored at −20 °C until use. 
 
MG-132 was obtained from Enzo Life Sciences, solubilised in DMSO and stored at 
4°C. 
 
BAY 11-7082 (E)-3-[(4-methylphenylsulfonyl]-2-propenenitrile was obtained from 
Enzo Life Sciences, solubilised in DMSO and stored at 4°C. 
 
PDTC (Pyrrolidine dithiocarbamate) were obtained from Sigma, solubilised in water 
and stored at -80°C. 
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NAC (N-acetyl-L-cysteine) was obtained from Sigma, solubilised in ethanol and 
stored at -20°C. 
 
Chloroquina diphosphate (CQ) [N4-(7-chloro-4-quinolinyl)-N1,N1-dimethyl-1,4-
pentanediamine] was obtained from Sigma, solubilised in water and stored at -20°C. 
 
3-Methyladenine was obtained from Sigma and solubilised in RPMI. The powder 
was stored at -20°C. 
 
Actinomycin D (ActD) was obtained from Sigma, solubilised in DMSO and stored 
at -80°C. 
 
Cell culture 
 
PaCa44, PaCa3, Panc1, CFPAC1, T3M4, and MiaPaCa2 cell lines were grown in 
RPMI 1640 supplemented with: 
 2 mM glutamine,  
 10% FBS, 
 50 µg/ml gentamicin sulfate (BioWhittaker). 
Primary fibroblasts (PromoCell) were grown in DMEM supplemented with: 
 2 mM glutamine,  
 10% FBS, 
 50 µg/ml gentamicin sulphate. 
All cells were incubated at 37 °C with 5% CO2. 
 
Cell proliferation assay 
 
Cells were plated in 96-well cell culture plates (5 × 103 cells/well) and treated with 
GEM and/or Cannabinoids. The compounds were added at the following range of 
concentrations:  
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Panc1, PaCa44 and PaCa3 cell lines: 
? 1 nM → 1 μM for GEM, 
? 80 nM → 80 μM for SR1 and GW405833,  
? 450 nM → 450 μM for ACPA.  
 
T3M4, CFPAC and MiaPaCa2 cell lines: 
? 0.2 nM → 200 nM for GEM,  
? 100 nM → 100 μM for SR1 and GW405833,  
? 560 nM → 560 μM for ACPA  
Cells were incubated for 48 h.  
At the end of the treatments, cell proliferation was evaluated by Crystal Violet 
(Sigma) staining with the following protocol: 
 
1. carefully remove culture medium from wells; 
2. wash plate gently with PBS at room temperature; 
3. carefully remove PBS and add crystal violet solution: 
4. incubate 5 minutes at room temperature; 
5. wash plate 2 times in tap water by immersion in a large beaker (be 
careful not to lift off cells and change tap water between washes); 
6. drain upside down on paper towels, than add 100 µl of  1% SDS in 
PBS 1X to solubilize the stain; 
7. agitate plate on orbital shaker until color is uniform with no areas of 
dense coloration in bottom of wells; 
8. read absorbance photometrically (A595 nm) to determine cell viability. 
 
Three independent experiments were performed for each assay condition.  
  
Time-dependent analysis 
 
Time-dependent growth curves of Panc1 and T3M4 cell lines treated with 
GEM/cannabinoids for 24 h. To maintain the molar ratios described above, Panc1 
cells were treated with 25 nM GEM and/or 2 μM SR1, 2 μM GW, or 11.25 μM 
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ACPA, while T3M4 cells were treated with 25 nM GEM and/or 12.5 μM SR1, 12.5 
μM GW, or 70 μM ACPA. 
The ratio on the Y axis was obtained by dividing the absorbance of untreated or 
treated cell lines by the mean absorbance of each cell line measured at time 0.  
 
Drug combination studies 
 
The combination index (CI) was calculated by the Chou–Talalay equation, which 
takes into account both the potency (IC50) and the shape of the dose–effect curve, by 
using the CalcuSyn software (Biosoft, Cambridge, UK).  
The general equation for the classic isobologram is given by 
 
CI=(D)1/(Dx)1+(D)2/(Dx)2+[(D)1·(D)2]/[(Dx)1.(Dx)2] 
 
where (Dx)1 and (Dx)2 in the denominators are the doses (or concentrations) for D1 
(drug 1) and D2 (drug 2) alone that gives X% growth inhibition, whereas (D)1 and 
(D)2 in the numerators are the doses of drug 1 and drug 2 in combination that also 
inhibited X% cell viability (i.e., isoeffective).  
 
The meaning of the CI value is: 
 
• CI<1    synergistic effect 
• CI=1    additive effect 
• CI>1    antagonistic effect 
 
In accordance to manufacturer instructions we further differentiated the synergistic 
effect in: 
 
• strong synergism (CI<0.3),  
• synergism (0.3<CI<0.7),  
• moderate synergism (0.7<CI<1).  
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CI/fractional effect curves represent the CI versus the fraction/percentage of cells 
affected/killed by drug combination. Indeed, the fractional effect is the % of growth 
inhibition corresponding to a given combination of the drugs. Dose reduction index 
(DRI) represents the measure of how much the dose of each drug in a synergistic 
combination may be reduced at a given effect level compared with the doses of each 
drug alone. 
The linear correlation coefficient (r) of the median–effect plot is considered the first 
line of statistics to measure the conformity of the data with the mass–action law 
principle when the experimental measurement is assumed to be accurate.  
Drug combination studies were performed using the following concentration ratios:  
 
 
 
GEM-sensitive cell lines 
 
[GEM]:[SR1] = 1:500 
[GEM]:[GW405833] = 1:500 
[GEM]:[ACPA] = 1:2800 
 
GEM-resistant cell lines 
 
[GEM]:[SR1] = 1:80 
[GEM]:[GW405833] = 1:80 
[GEM]:[ACPA] = 1:450 
 
 
 
 
 
These molar ratios were calculated on the basis of GEM and cannabinoids IC50 mean 
values at 48 h. For GEM they correspond to 36 nM for the three GEM-sensitive cell 
lines tested and 220 nM for the three GEM-resistant cell lines tested. 
The three cannabinoids were similarly effective in the six cell lines with IC50 mean 
values corresponding to 18 μM for SR1 and GW405833 and 100 μM for ACPA. 
 
Analysis of reactive oxygen species (ROS) 
 
The non-fluorescent diacetylated 2',7'-dichlorofluorescin (DCF-DA) probe, which 
becomes highly fluorescent on reaction with ROS, was used to evaluate intracellular 
ROS production.  
Cells were plated in 96-well plates (5 x 103 cells/well) and the day after treated with 
the various compounds for 4 h and 16 h at the constant dose ratio: 
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GEM   
100-200-500 nM in Panc1 cells 
 16-32-80 nM in T3M4 cells 
 
GW405833 and SR1 
 8-16-40 µM 
 
ACPA 
 40-90-225 µM 
 
Then, cells were incubated with 10 µM DCF-DA (Sigma) for 15 min at 37 °C and 
then the DCF fluorescence was measured by using a multimode plate reader (Ex 
485nm and Em 535nm). 
 
RNA extraction with TRIzol, qPCR, RT-PCR and image 
analysis
 
1. Cell lysis: 
? add 1 ml of TRIzol at the cells, 
? homogenise by pipetting several times (mechanic lysis), 
? keep 5 min at RT for complete dissociation of nucleoprotein 
complexes. 
2. Phase separation: 
? add 0.2 ml of chloroform to 1 ml of TRIzol, 
? shake for 15 sec, 
? incubate 2-5 min at RT, 
? spin 12000g, 15 min at 4°C. 
3. RNA precipitation: 
? transfer aqueous upper phase into new tube, 
? add 0.5 ml of isopropanol to 1 ml of TRIzol, 
? incubate 10 min at RT, 
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? spin 12000 g, 10 min at 4ºC. 
4. RNA wash: 
? remove supernatant, 
? wash pellet with 75% EtOH (1 ml EtOH to 1 ml of TRIzol), 
? spin 7500 g, 5 min at 4ºC. 
5. Redissolving of RNA: 
? air-dry pellet for 5-10 min, 
? dissolve pellet in 50µl of H2O RNase free, 
? incubate at 55-60 C° for 10 min 
? quantify the RNA. 
 
For qPCR, the primers used were:  
CB1 For  5’-GAGAGGTGCCAAGGGAGCTT-3’  
CB1 Rev  5’-GGTGCGGAAGGTGGTATCTG-3’;  
 
CB2 For  5’-CACAGCCTCTGTGGGTAGCC-3’  
CB2 Rev  5’-ACGGGTGAGCAGAGCTTTGT-3’;  
 
Grp78 For  5’-GACGGGCAAAGATGTCAGGAA-3’  
Grp78 Rev  5’-TCATAGTAGACCGGAACAGATCCA-3’;  
 
CHOP For  5’-GCAGCCCATGAAGGAGAAAG-3’  
CHOP Rev  5’-CGGTCGATTTCCTGCTTGAG-3’,  
 
GAPDH For  5’-TGTGTCCGTCGTGGATCTGA-3’  
GAPDH Rev  5’-R-GATGCCTGCTTCACCACCTT-3’.  
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The following cycling conditions were used: 95 °C for 10 min, 40 cycles at 95 °C for 
15 s, 60 °C for 1 min and 72 °C for 30 s. The average of cycle threshold (CT) of each 
triplicate was analyzed according to the 2(-ΔΔCt) method.  
For RT-PCR, one tenth of the cDNA was used as a template for PCR amplification 
using the following primers and cycling conditions:  
 
β-actin For  5′-ACCAACTGGGACGACATGGAGAA-3′  
β-actin Rev  5′-GTGGTGGTGAAGCTGTAGCC-3′,  
 
25 cycles of 94 °C for 60 s, 55 °C for 60 s and 72 °C for 60s;  
 
XBP-1 For  5′-CCTTGTAGTTGAGAACCAGG-3′  
XBP-1 Rev  5′-GGGGCTTGGTATATATGTGG-3′,  
 
40 cycles of 93 °C for 60 s, 55 °C for 60 s and 72 °C for 60 s.  
 
PCR products were separated by electrophoresis through ethidium bromide-stained 
3.5% agarose gel and visualized by ultraviolet light. To quantify XBP-1 splicing, 
XBP-1(S) bands were scanned as digital peaks and the areas of the peaks were 
calculated using the public domain NIH Image software 
(http://rsb.info.nih.gov/nihimage/), normalized with β-actin mRNA expression, and 
reported as fold induction relative to controls. 
For actinomycin D experiments, 2.5 x 105 Panc1 cells were seeded in 60 mm plates 
and incubated overnight. Cells were pre-treated with 0.5 µg/µl Actinomycin D for 1 
hour, then 2 µM GEM was added and the treatments prolonged up to 16 hours. Total 
RNA extraction and real-time PCR were performed as above described. 
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Apoptosis 
 
The percentage of apoptotic cells was evaluated by staining 3 × 105 cells with 
annexin V-FITC (Bender Med System) and 5 µg/ml propidium iodide in binding 
buffer for 10 min at room temperature in the dark. 
The samples were analyzed by flow cytometry (FACScalibur, Becton-Dickinson) to 
determine the percentage of cells displaying:  
 
 
Early apoptosis 
 
Annexin V+ / propidium 
iodide- staining 
Late apoptosis 
 
Annexin V+ / propidium iodide+ 
staining 
 
 
 
 
 
Cells were treated with 200 nM GEM and/or 16 μM SR1, 90 μM ACPA, or 16 μM 
GW405833 for 48 h. 
 
BINDING BUFFER: 
10 mM HEPES/NaOH (pH 7.4),  
140 mM NaOH, 
2.5 mM CaCl2.  
 
Cell cycle analysis 
 
Cell cycle distribution was analyzed using propidium iodide (PI)-stained cells.  
Cells were: 
1. washed with PBS,  
2. incubated with: 
? 0.1% sodium citrate dihydrate,  
? 0.1% Triton X-100, 200 μg/ml RNase A, 
? 50 μg/ml propidium iodide (Roche Molecular Biochemicals) 
3. analyzed using a flow cytometer (FACScalibur, Becton Dickinson). 
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The percentage of cells in the various stages of the cell cycle was determined using 
the ModFitLT software. 
Cells were treated with 200 nM GEM and/or 16 μM SR1, 90 μM ACPA, or 16 μM 
GW405833 for 48 h.  
 
Immunoblot analysis 
 
Cells were plated in cell culture plates (1.2 × 106 cells/plate). Western blot analysis of 
LC3 was performed using total protein extracts from Panc1 cells treated with 500 nM 
GEM and/or 40 μM GW, 225 μM ACPA SR1, or 40 μM SR1 for 24 h. The 
concentration of NAC (N-acetyl-L-cysteine) was 10 mM. 
 
1. At the end of the treatments cells were: 
? collected,  
? washed in phosphate-buffered saline,  
? resuspended in RIPA buffer pH 8,  
? kept for 30 min on ice.   
2. The lysate was centrifuged at 14,000×g for 10 min at 4 °C and the 
supernatant was used for Western blot.  
3. Protein concentration was measured with the Bradford protein assay reagent 
(Pierce) using bovine serum albumin as a standard. Fifty (LC3-II) or thirty 
(Grp78) micrograms of protein extracts were electrophoresed through a 15% 
SDS-polyacrylamide gel and electro-blotted onto PVDF membranes 
(Millipore, Bedford, MA). 
4. Membranes were then incubated for 2 h at room temperature with blocking 
solution and probed overnight at 4 °C with the appropriate primary antibody 
[1:1000 in blocking solution of LC3B (Cell Signaling) or α-tubulin 
(Oncogene) antibodies]. 
5. Horseradish peroxidase conjugated IgG (1:2000 in blocking solution, Upstate 
Biotechnology) was used to detect specific proteins. 
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6. Immunodetection was carried out using chemiluminescent substrates 
(Amersham Pharmacia Biotech) and recorded using a HyperfilmECL 
(Amersham Pharmacia Biotech).  
 
To quantify the autophagy, LC3 bands were scanned as digital peaks and the areas of 
the peaks relative to LC3-II were calculated in arbitrary units using the public 
domain NIH Image software (http://rsb.info.nih.gov/nihimage/) and reported as fold 
induction relative to controls. α-tubulin was used as a normalizing factor.  
The choice to consider only the amount of LC3-II for autophagy analysis, rather than 
LC3-II/LC3-I ratio, was derived from the evaluation performed by Mizushima et 
Yoshimori. 
 
 RIPA buffer pH8 
150 mM NaCl; pH 8,  
50 mM Tris-HCl; 
1% NP-40;  
0.5% Na-Doc;  
0.1% SDS; 
1 mM PMSF; 
1 mM Na3VO4; 
1 mM NaF;  
2.5 mM EDTA; 
1× protease inhibitor cocktail (Roche)  
 
Western blot solution: 
 
RUNNING BUFFER: 
 25 mM Tris-HCl, pH 8.3   
 190 mM Glycine     
 SDS 0.1%      
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BLOCKING SOLUTION: 
5% low-fat milk in TBST 1X 
 
TBST: 
100 mM Tris, pH 7.5 
NaCl 0.9% 
Tween 20 0.1% 
 
TRANSFER BUFFER: 
 25 mM Tris-HCl, pH 8.3   
 190 mM Glycine         
150 ml MetOH 
 
SAMPLE BUFFER 4X: 
 200 mM Tris-HCl, pH 6.8  
 SDS 8%      
 Glycerol 40%    
  Bromophenol blue 0.4% 
 
Labeling of autophagic vacuoles with monodansylcadaverine 
(MDC) 
 
To quantify the induction of the autophagic process in Panc-1 cells treated with the 
various compounds as indicated in the legend, MDC staining was performed as 
previously described [35]. Following the treatments, cells were incubated with 50 
μM MDC in PBS at 37°C for 15 min. After incubation, cells were washed with PBS, 
trypsinized and immediately analyzed by flow cytometry. All fluorescences were 
analyzed with a FACScalibur flow cytometer (Becton Dickinson, California). The 
fluorescent emissions were collected through a 530 nm band pass filter (FL1 
channel). At least 10,000 events were acquired in log mode. For the quantitative 
evaluation of MDC, CellQuest software (Becton Dickinson) was used to calculate 
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mean fluorescence intensities (MFIs). The MFIs were calculated by the formula 
(MFItreated/MFIcontrol), where MFItreated is the fluorescence intensity of cells 
treated with the various compounds and MFIcontrol is the fluorescence intensity of 
untreated and unstained cells. 
 
Quantification of acidic vescicle organelles with acridine 
orange 
 
In acridine orange-stained cells, the cytoplasm and nucleus are bright green and dim 
red, whereas acidic compartments are bright red. The intensity of the red 
fluorescence is proportional to the degree of acidity. Following the treatments as 
specified in the legend, cells were incubated with acridine orange solution (1 μg/ml) 
at 37˚C; after 15 min in drug-free medium at 37˚C, they were washed with PBS, 
immediately stained with 1 μg/ml of acridine orange for 15 min, and observed with a 
Nikon Eclipse TE300 Inverted microscope. 
Then, cells were trypsinized and analyzed by flow cytometry using FACScan 
cytometer and CellQuest software, as previously described. 
 
In vivo studies 
On the basis of our previous experience, we did not use Panc1 cells for in vivo studies 
because of their low growth rate in nude mice. Thus, we chose PaCa44 cells for their 
very similar behaviour to Panc1 cells after GEM/cannabinoid treatments in vitro. 
PaCa44 cells (2 × 106 cells/mice) were s.c. injected into female nude mice (4 weeks 
of age, Harlan laboratories). One week after cell inoculation, 5 randomized animals 
for each experimental group received solution vehicle (PBS), 25 mg/Kg GEM, or/and 
0.28 mg/Kg SR1 by intraperitoneal injection biweekly for 4 weeks. Although drug 
molar ratios are different to that used in our in vitro studies, drug doses were chosen 
on the basis of their respective clinical use following US Food and Drug 
Administration directives. Tumour volume and body mass were biweekly recorded 
for each animal. Animals were sacrificed at the end of the 4-week study period and 
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the tumours were resected and weighted. The animal studies were approved by the 
Verona University Review Board. 
 
Statistical analysis 
 
ANOVA (post hoc Bonferroni) analysis was performed by GraphPad Prism version 
5. P values less than 0.05 or 0.01 were indicated as ** or ***, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 47
Results 
 
 
 
 
Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 48
Results 
Results 
 
The cannabinoids GW, ACPA, and SR1 inhibit pancreatic 
adenocarcinoma cell proliferation 
 
The inhibition of cell proliferation by GW (GW405833 hydrochloride), ACPA 
(arachidonoyl cyclopropamide), and SR1 (SR141716) was examined 
by measuring the growth of six pancreatic adenocarcinoma cell lines 
at 48 hours following treatment with increasing concentrations of cannabinoids. All 
cell lines analyzed showed a strong inhibition of growth 
(Fig. 10 ), with an average IC  value corresponding to 18 50 μM for GW and SR1 and 
110 μM for ACPA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: The cannabinoids inhibit the proliferation of six cell lines of pancreatic 
adenocarcinoma. The cells were treated with increasing concentrations of GW, SR1, 
and ACPA for 48 hours and the cell proliferation was measured using crystal 
violet. The values presented are the mean of three independent experiments. 
 49
Results 
Cell proliferation assay after GEM/cannabinoid treatment 
 
To investigate if the synthetic cannabinoids SR1, ACPA, and GW were able to 
enhance cell growth inhibition induced by GEM, we performed dose-dependent 
analyses of cell viability on six pancreatic adenocarcinoma cell lines. 
As established in previous analyses, the IC50 at 48 hours of treatment with GEM is 
different for the six tumor cell lines studied:  
- PaCa44, Panc1 and PaCa3 are more resistant to GEM treatment and have an 
average IC50 of 220 nM (R lines) 
- MiaPaCa2, T3M4 and CFPAC1 are more sensitive to GEM treatment and 
have an average IC50 of 36 nM (S lines) [12].  
In the combination studies with GEM/cannabinoids, we chose two different molar 
ratios for the two groups of cell lines, R and S, based on the mean IC50 of 
cannabinoids and GEM. The molar ratio was: 
• for the resistant cell lines 
- (1:80) for GEM/GW and GEM/SR1 
- (1:450) for GEM/ACPA 
• for the sensitive cell lines 
- (1: 500) for GEM/GW and GEM/SR1 
- (1:2800) for GEM/ACPA 
Figure 11 shows the cell viability of Panc1 and T3M4 cell lines after 48 h treatment 
with increasing concentrations of single or combined drugs. At the higher 
concentrations, cannabinoids, but not GEM, were generally able to totally inhibit cell 
viability. In the combined treatments, proliferation of Panc1 cells was further 
inhibited in almost all conditions, while that of T3M4 cells was only sporadically 
reduced. Similar results were obtained with the other pancreatic adenocarcinoma cell 
lines tested in this study.  
The antiproliferative effect of the combination GEM/cannabinoids, as compared to 
single-drug treatments, was stronger in GEM-resistant than in GEM-sensitive cell 
lines. By inverting the molar ratios of the compounds between the two groups of cell 
lines, no significant alteration of the results was observed, indicating that the 
differential behaviour was not due to the specific experimental condition tested. 
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Figure 11: Effect of increasing concentrations of GEM and/or the cannabinoids SR1, 
ACPA, or GW on Panc1 and T3M4 pancreatic adenocarcinoma cell growth. The 
compounds were added at the following range of concentrations: 1 nM → 1 µM for 
GEM, 80 nM → 80 µM for SR1 and GW405833, 450 nM → 450 µM for ACPA in 
Panc1 cell line; 0.2 nM → 200 nM for GEM, 100 nM → 100 µM for SR1 and 
GW405833, 560 nM → 560 µM for ACPA in T3M4. GEM concentration for each 
condition corresponds to: 1, 2, 5, 10, 20, 50, 100, 200, 500 nM, and 1µM for Panc1 cells 
and 0.2, 0.5, 1, 2, 5, 10, 20, 50, 100, and 200 nM for T3M4 cells. Cells were incubated 
for 48 h. Empty triangle, empty circle, and black rhombus correspond to GEM, 
cannabinoids, and combined treatments, respectively. Values are the means of triplicate 
wells from three independent experiments. 
Results 
To examine the sensitivity of normal cells to GEM/cannabinoid treatments, we 
performed cell viability analyses on human primary fibroblasts. Drug combinations 
were not able to increase the cytotoxic effect of GEM or cannabinoids alone, both 
with the drug molar ratios used for GEM-resistant and GEM-sensitive cell lines 
(Figure 12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Effect of increasing concentrations of GEM and/or the cannabinoids 
SR1, ACPA, or GW on normal fibroblast cell growth. The compounds were added at 
the following range of concentrations: 1 nM → 1 µM for GEM, 80 nM → 80 µM for 
SR1 and GW405833, 450 nM → 450 µM for ACPA. GEM concentration for each 
condition corresponds to: 1, 2, 5, 10, 20, 50, 100, 200, 500 nM, and 1µM. Cells were 
incubated for 48 h. Empty triangle, empty circle, and black rhombus correspond to 
GEM, cannabinoids, and combined treatments, respectively. Values are the means of 
triplicate samples from three independent experiments. 
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The combined treatment GEM/cannabinoid synergistically 
inhibits pancreatic adenocarcinoma cell proliferation 
 
To evaluate whether cell growth inhibition by GEM/cannabinoids was synergistic, 
we analyzed the cell viability curves by using the dedicated software CalcuSyn. 
Figure 13 reports the isobolograms of the combination index (CI) values versus the 
fraction (0→1) of cells killed by the different drug combinations in the GEM-
resistant cell lines. All combinations gave rise to a significant synergistic reduction 
of cell viability. 
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Figure 13
 
: Combination index (CI)/fractional effect curves of the antiproliferative 
effect after 48 h treatment of Panc1 (see fig. 1), PaCa3, and PaCa44 cell lines with 
increasing concentrations of GEM/cannabinoids. The values on the X-axis 
correspond to the fraction of growth inhibition by increasing concentrations of drug 
combinations.  
 
 
Results 
Figures 14 and 15 report the percentages of the Combination Index (CI) values 
encompassed between 1 and 0.3 (synergism) or lower than 0.3 (strong synergism) for 
all combinations. Although GEM resistant cell lines showed similar percentages of 
overall synergism to GEM sensitive cell lines, it is worth to note that the former cell 
lines show a significant higher level of strong synergism (CI<0.3) compared to the 
latter cell lines, as reported in figure 14. Instead, GEM/cannabinoids did not 
determine any synergisms in normal fibroblasts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Percentages of GEM/cannabinoid antiproliferative synergism in six 
pancreatic adenocarcinoma cell lines and normal fibroblasts. The percentage values 
were obtained by analyzing CI/effect curves.  Statistical analysis: p<0.001, % CI<1 
in all cancer cell lines versus normal fibroblasts. 
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Figure 15: GEM/cannabinoids determined a significant 
antiproliferative strong-synergism (CI<0.3) in GEM-resistant as 
compared to GEM-sensitive cell lines and normal fibroblasts. 
The percentage values were obtained by analyzing CI/effect 
curves 
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As shown in figure 16, a good correlation exists between the GEM IC50 values of the 
six cell lines and the synergism/strong synergism (CI<0.7) obtained with all 
GEM/cannabinoid combinations. 
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Figure 16: Correlation between GEM resistance and GEM/cannabinoid 
antiproliferative synergism. The CI/effect curves were analysed to determine the CI 
values for each 0.05 fraction of the effect. The mean percentage values of synergism 
(CI<0.7) were plotted versus the GEM IC50 at 48 h for each pancreatic 
adenocarcinoma cell line. 
Results 
To analyze the trend of the inhibitory effect over the time, we performed a time-
dependent analysis of the antiproliferative activity following a 24 h single-step 
treatment with GEM and/or cannabinoids. Figure 17 shows that starting from the 
fourth day the combined, but not the single treatments, were able to significantly 
inhibit Panc1 cell proliferation, with a growth rate inhibition at the sixth day in 
treated versus untreated cells of 48%, 36%, and 57% for GEM/GW, GEM/ACPA, 
and GEM/SR1, respectively, but not T3M4 cell proliferation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 17
 
 
 
 
 
 
: Effect of GEM and/or GW, ACPA, or SR1 on growth of pancreatic 
adenocarcinoma Panc1 and T3M4 cells. The cells were seeded in 96-well plates and 
incubated overnight. The compounds were added at the following concentrations for 24 h: 
25 nM GEM and/or 2 µM SR1, 2 µM GW, or 11.25 µM ACPA. The growth ratio on the 
Y-axis was obtained by dividing the absorbance of untreated or treated cell lines by the 
mean absorbance of each cell line measured at time 0. Star, empty triangle, empty circle, 
and black rhombus correspond to control, GEM, cannabinoids, and combined treatments, 
respectively. Values are the means of triplicate samples from three independent 
experiments (±SD). The statistical analysis reported was performed for each combined 
treatment versus control. 
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Results 
GEM/cannabinoids enhance intracellular ROS production 
 
Previously published data of our group have reported that GEM is able to induce 
ROS and that an inverse correlation exists between resistance to GEM and 
constitutive ROS levels in pancreatic adenocarcinoma cells [11]. To verify whether 
SR1, ACPA, or GW further enhanced ROS production by GEM, we measured ROS 
levels in Panc1 and T3M4 cells treated with increasing doses of the drugs. Figure 18 
shows that 4 h GEM/cannabinoid treatments determined a significant enhancement 
of ROS relative to single treatments in Panc1, but not in T3M4 cells. Similar results 
were obtained after 16 h or by inverting the molar ratios of the compounds between 
the two cell lines. 
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Figure 18: Effect of GEM and/or cannabinoids on intracellular ROS production 
in Panc1 and T3M4 cell lines. Cells were treated with increasing concentrations 
of the compounds for 4 h at the constant dose ratios. The 2′,7′-dichlorofluorescin 
(DCF) fluorescence intensity, corresponding to the level of ROS production, was 
measured by a multimode plate reader. Empty triangle, empty circle, and black 
circle correspond to GEM, cannabinoids, and combined treatments, respectively. 
Values are the means of triplicate samples from three independent experiments. 
The statistical analysis was performed for each combined treatment versus single 
treatments.   
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Results 
To analyze the functional role of ROS enhancement in the synergistic 
antiproliferative effect by combined treatments, we used a non-toxic concentration 
(10 mM) of the antioxidant compound N-acetyl-L-cysteine (NAC) that was able to 
completely abolish ROS induction by GEM/cannabinoids. Figure 19 and data 
analysis by the CalcuSyn software reveal that NAC addition abolished the enhanced 
cell growth inhibition and the antiproliferative synergism by all three combined 
treatments in Panc1 cells. 
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Figure 19: Effect of increasing concentrations of GEM and/or cannabinoid compounds 
SR1, ACPA, or GW405833 on Panc1 cells in the presence of 10 mM NAC. Cells were 
seeded in 96-well plates and incubated overnight. The day after cells were pre-treated with 
10 mM NAC for 1 h and then treated for 48 h with the various compounds at the 
following range of concentrations: 1 nM → 0.5 µM for GEM, 80 nM → 40 µM for SR1 
and GW405833, 450 nM → 225 µM for ACPA. Each condition corresponds to a GEM 
concentration of: 1, 2, 5, 10, 20, 50, 100, 200, and 500 nM. Empty triangle, empty circle, 
and black circle correspond to GEM, cannabinoids, and combined treatments, 
respectively. Values are the means of triplicate samples from three independent 
experiments. 
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GEM induces cannabinoid receptor expression by NF-кB 
mediated mechanism 
 
Since it was described that cannabinoid receptor overexpression was a mechanism 
able to potentiate cannabinoid effect [36], we investigated whether GEM induces 
CB1 and CB2 receptor expression in Panc1 cells. As shown in figure 20, GEM 
determined a 4.4-fold induction of CB1 mRNA at 24 h and a 7.7-fold induction of 
CB2 mRNA at 16 h.  
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Figure 20: Analysis of CB1 and CB2 cannabinoid receptor gene 
induction by GEM in Panc1 cells. qPCR assay was performed on cells 
treated with 2 µM GEM at the indicated time points. Values are the 
means of three independent experiments. The statistical analysis 
reported was relative to GEM treatment versus control. 
 
 
CB mRNAs induction by GEM was transcriptionally regulated, as indicated by their 
complete inhibition following Actinomycin D treatment (Figure 21) and was 
reversed by three NF-κB inhibitors (BAY, PDTC, and MG132), but not by the free 
radical scavenger NAC (Figure 22). 
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Figure 22: qPCR analysis of CB1 and CB2 gene induction by 2 µM GEM alone or in 
combination with 10 mM NAC, 100 µM MG132, 10 µM BAY, or 100 µM PDTC 
which were added 1 h before. CB1 and CB2 gene expression was analyzed at 24 h and 
16 h, respectively. Values are the means of triplicate samples from three independent 
experiments (±SD). p<0.001 control versus GEM or GEM+NAC; p<0.001 GEM 
versus GEM+MG132, GEM+BAY, or GEM+PDTC. The same significance was 
observed for both CB1 and CB2. 
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Figure 21: Panc1 cells were seeded in 60 mm plates and incubated overnight. 
Cells were pre-treated with 0.5 μg/μl Actinomycin D for 1 hour, then 2 μM 
GEM was added and the treatments prolonged up to 16 hours. Total RNA 
extraction and real-time PCR were performed as described in Materials and 
Methods.  Values are the means of triplicate samples from four independent 
experiments (±SD). Statistical analysis: *** p<0.001, ** p<0.01.  
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IL-1, a known NF-κB inducer, was able to stimulate CB1 and CB2 induction and 
both GEM and IL-1-mediated cannabinoid receptor enhancement was dramatically 
increased by the addition of the histone deacetylase inhibitor TSA. Furthermore, the 
addition of the NF-κB inhibitor MG132 completely reversed these effects (figure 
23).  
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Figure 23: qPCR analysis of CB1 and CB2 gene induction by the indicated 
treatments using 2 µM GEM, 0.2 µM TSA, 100 µM MG132, and 10 µg/ml IL-1. 
CB1 and CB2 gene expression was analyzed at 24 h and 16 h, respectively. Values 
are the means of triplicate samples from three independent experiments (±SD). 
p<0.001 GEM versus GEM+TSA or GEM+TSA+MG132 (for both CB1 and CB2); 
p<0.001 IL-1 versus IL-1+TSA and IL-1+TSA versus IL-1+TSA+MG132 (for both 
CB1 and CB2). 
 
 
Altogether, these data strongly suggest that NF-κB is involved in cannabinoid 
receptor induction by GEM with a ROS-independent mechanism. 
To verify if the cannabinoid receptors induction by GEM has a role in the synergy, 
we used 1 µM BAY and 100 nM MG132. Figure 24 shows that both NF-κB 
inhibitors are able to significantly reduce the antiproliferative synergism by all three 
combined treatments in Panc1 cells. 
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Figure 24: Analysis of the antiproliferative synergism by 2 μM GEM and 40 
µM GW, 225 µM ACPA, or 40 µM SR1, in the absence or presence of 100 
nM MG132 or 1 μM BAY. Values are the means of three independent 
experiments (±SD). Statistical analysis for total synergism (0.3<CI<1): 
p<0.001 GEM+GW versus GEM+GW+BAY, p<0.001 GEM+ACPA versus 
GEM+ACPA+BAY and p<0.001 GEM+SR1 versus GEM+SR1+MG or 
GEM+SR1+BAY; p<0.05 GEM+GW versus GEM+GW+MG and p<0.05 
GEM+ACPA versus GEM+ACPA+MG. Statistical analysis for high 
synergism (CI<0.3): p<0.001 GEM+GW versus GEM+GW+MG or 
GEM+GW+BAY and p<0.001 GEM+SR1 versus GEM+SR1+BAY; p<0.01  
GEM+ACPA versus GEM+ACPA+BAY and p<0.01 GEM+SR1 versus 
GEM+SR1+BAY; and p<0.05 GEM+ACPA versus GEM+ACPA+MG.   
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These data indicate that NF-ĸB is involved in cannabinoid receptor induction by 
GEM with a ROS-independent mechanism and in the antiproliferative synergism by 
GEM/cannabinoids, suggesting a role for CB1 and CB2 activation by GEM in the 
latter effect..  
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GEM enhances cannabinoid-induced ER stress 
 
It was described that ER stress is a molecular mechanism involved in cannabinoid 
antiproliferative effect [17]. To investigate whether GEM was able to enhance the 
cannabinoid-induced ER stress we analyzed XBP-1, Grp78, and CHOP mRNA 
expression. We show that XBP-1(S), Grp78, and CHOP mRNA levels were 
increased by GW, ACPA, or SR1 and, although GEM alone was ineffective, they 
were further significantly enhanced by the addition of GEM (figure 25). 
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Figure 25: Effect of GEM and/or cannabinoids on ER stress-related genes in Panc1 
cells. Cells were treated with 500 nM GEM and/or 40 µM GW, 225 µM ACPA, or 40 
µM SR1 for 8 h. Values are the means of triplicate samples from three independent 
experiments (±SD). p<0.001 GEM versus each cannabinoid; p<0.001 each 
cannabinoid versus its combination with GEM (for all three genes). 
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GEM/cannabinoid combination’s  effect on apoptosis and cell 
cycle 
 
It has been demonstrated that GEM or cannabinoids can induce the apoptotic cell 
death program and a cytostatic mechanism [36]. To determine whether apoptosis and 
cell cycle arrest are involved in the antiproliferative synergism between GEM and 
cannabinoids, we performed annexin V-FITC/propidium iodide assay and cell cycle 
analysis by flow cytometry after single or combined treatments. Cells were treated 
with 200 nM GEM and/or 16 µM GW, 90 µM ACPA, or 16 µM SR1 for 48 h and 
analyzed by flow cytometry.  
Figure 26 shows that at 48 h GEM, but not cannabinoids, significantly induced 
apoptosis while this effect was partially reduced by the addition of cannabinoids in 
Panc1 cells. Similar results were obtained at 24 h and in PaCa44 and T3M4 cell 
lines.  
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Figure 26: Analysis of apoptosis by GEM and/or cannabinoids in Panc1 
cells. Cells were treated with 200 nM GEM and/or 16 µM GW, 90 µM 
ACPA, or 16 µM SR1 for 48 h and analyzed by flow cytometry to determine 
the percentages of apoptotic cells. Values are the means of three independent 
experiments (±SD). p<0.001 control versus GEM; p<0.05 control versus 
each combination; p<0.01 GEM versus each combination. No significance 
was observed between control and each cannabinoid. 
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Figure 27 and table 3 shows that GEM increased the percentages of cells in G1 and S 
phases and cannabinoids in G1 phase, and the combined treatments did not induce a 
potentiation of the accumulation of cells in a particular phase of cell cycle when 
compared with the changes induced by GEM or cannabinoids alone.  
 
 
Figure 27: Analysis of cell cycle by GEM and/or cannabinoids 
in Panc1 cells. Cells were treated with 200 nM GEM and/or 16 
µM GW, 90 µM ACPA, or 16 µM SR1 for 48 h. Cell cycle 
distribution was analyzed by a flow cytometer after DNA 
staining with propidium iodide. Values are the means of three 
independent experiments (±SD). No significance was observed 
between GEM or each cannabinoid versus their combinations. 
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Table 3: Effect of gemcitabine and/or cannabinoids on cell cycle 
distribution in Panc1 cell line. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Altogether these data indicate that GEM/cannabinoid synergism was not mediated by 
either an apoptotic or a cytostatic event. 
  
GEM enhances cannabinoid-induced autophagy by a ROS-
mediated mechanism 
 
Recently, it has been reported [17] that THC is able to induce autophagy-mediated 
cell death in human glioma cells. We therefore investigated whether also GW, 
ACPA, or SR1 were able to induce autophagy and whether this effect could be 
further enhanced by GEM. Cells were treated with 500 nM GEM and/or 40 µM GW, 
225 µM ACPA, or 40 µM SR1 for 24 h in the presence of acid lysosomial protease 
inhibitors E64d (10 µM) and pepstatin A (10 µg/ml).  Interestingly, figure 28 and 29 
shows that LC3-II protein, the phospho-ethanolaminated form of the autophagosome 
protein LC3-I, was induced by GEM or the cannabinoids alone and that it was further 
significantly enhanced by the combined treatments at 24 h. Similar results were 
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observed at 48 h. These data reveal that GEM was able to potentiate the cannabinoid-
induced autophagic event. 
 
 
Figure 28: Analysis of autophagy in Panc1 cells treated with 
GEM/cannabinoids. Western blot analysis of LC3 was performed using 
total protein extracts from Panc1 cells treated with 500 nM GEM and/or 40 
µM GW, 225 µM ACPA SR1, or 40 µM SR1 for 24 h in the presence of 
acid lysosomial protease inhibitors E64d (10 µM) and pepstatin A (10 
µg/ml). Similar data were obtained after 48 h treatments. 
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Figure 29: Densitometric analysis of LC3-II bands 
normalized to α-tubulin. Values are the means of three 
independent experiments. Statistical analysis: p<0.01 
control versus GW or ACPA, p<0.05 control versus 
SR1, p<0.01 each cannabinoid versus its combination.  
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Figure 30 shows that the addition of  20 mM NAC to the combined treatments 
significantly reduced LC3-II expression indicating that oxidative stress is involved in 
the autophagic event induced by GEM/cannabinoids. 
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Figure 30: Analysis of autophagy by 500 nM GEM and 40 µM 
GW, 225 µM ACPA, or 40 µM SR1, in the absence or presence 
of 20 mM NAC. Values are the means of three independent 
experiments (±SD). p<0.001 GEM/cannabinoids versus 
GEM/cannabinoids+NAC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A late step in the autophagic cell death process is the fusion of lysosomes with 
autophagosomes into autolysosomes, which can be detected by measuring their 
acidification with acridine orange staining. Figure 31 show that acridine orange 
staining (characterized by a punctuature suggesting vacuole formation) slightly 
increased in GEM-treated cells and significantly potentiated in cells treated with 
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GEM/cannabinoids combinations and that these effects were almost completely 
antagonized by the addition of either the scavenger NAC or the autophagy inhibitors 
3-methyladenine (3-MA), an inhibitor of the class III phosphatidylinositol 3-kinase 
(class III PI3K) complex involved in initial autophagosome formation and the 
lysosomal hydrolasis inhibitor clorochine (CQ).  
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Figure 31: Fluorescence microscopy analysis of autophagosomes 
formation in Panc1 cells after acridine orange staining treated with 500 
nM GEM and 40 µM GW, 225 µM ACPA, or 40 µM SR1, in the absence 
or presence of 20 mM NAC or10 µM CQ or 1mM 3MA for 24 h. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This observation was quantified and confirmed by FACS analyses and illustrates a 
significant difference in the acidification of the acidic vesicular organelles (AVOs) in 
GEM and GEM/cannabinoids combination-treated pancreatic cancer cells. Blocking 
autophagy with 3-MA or CQ resulted in a decrease in autolysosomal acidification, 
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demonstrating that acidification induced by the different combinations was linked to 
the autophagic pathway (figure 32).  
 
Figure 32: Mean fluorescence intensities (MFIs) were 
calculated  FACS after trypsinization of the acridine 
orange labelled cells. Values are the means of triplicate 
samples from three independent experiments (±SD). 
Statistical analysis: p<0.05 control versus GEM, GW, 
ACPA, or SR1, p<0.001 each cannabinoid or GEM 
versus their combination, p<0.001 GEM/cannabinoids 
versus GEM/cannabinoids+ NAC, GEM/cannabinoids+ 
CQ or GEM/cannabinoid+3-MA. 
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To ascertain if the presence of numerous cytoplasmic vacuoles in GEM/combination-
treated cells was really due to the induction of autophagy, the autofluorescent drug 
monodansylcadaverine (MDC), a selective marker for AVOs. The quantitative 
evaluation of MDC staining performed by FACS. We have found again that GEM, 
SR1 and ACPA induced a similar increase of AVO formation that was more 
prominent in GW-treated cells and this effect was strongly potentiated by the 
GEM/cannabinoids combinations. Again the addition of the autophagy inhibtors CQ 
or 3MA or the scavenger NAC antagonized this effect (figure 33). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GEM+GW GEM+SR1 GEM+ACPA
ACPA
SR1
GEM
CTR
GW
+NAC
+3MACTR
+CQ
GEM + cannabinoids
C
T
R
L
G
E
M
+N
A
C
+C
Q
+3
M
A
GEM+GW
M
FI
0
20
40
60
400
500
SR
1
A
C
PA G
W
+N
A
C
+C
Q
+3
M
A
GEM+SR1
+N
A
C
+C
Q
+3
M
A
GEM+ACPA
C
T
R
L
G
E
M
+N
A
C
+C
Q
+3
M
A
M
FI
SR
1
A
C
PA G
W
+N
A
C
+C
Q
+3
M
A
+N
A
C
+C
Q
+3
M
A
Figure 33: Flow cytometric analyses of autophagosomes formation (MDC 
incorporation) in Panc1 cells treated with 500 nM GEM and 40 µM GW, 225 µM 
ACPA, or 40 µM SR1, in the absence or presence of 20 mM NAC or 10 µM CQ or 
1mM 3MA for 24 h. Values are the means of three independent experiments (±SD). 
Statistical analysis: p<0.01 control versus GEM, SR1, or ACPA, p<0.001 control 
versus GW, p<0.001 each cannabinoid or GEM versus their combination, p<0.001 
GEM/cannabinoids versus GEM/cannabinoids+NAC, GEM/cannabinoids+CQ, or 
GEM/cannabinoid+3-MA. 
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To test if the GEM/cannabinoids antiproliferative synergism was due to autophagy, 
we used again 3-MA and CQ. The analysis of antiproliferative synergism was made 
with  500 nM GEM and 40 µM GW, 225 µM ACPA, or 40 µM SR1 in the absence 
or presence of 2,5 mM 3-MA or 10 µM CQ. Both 3-MA or CQ strongly reduced the 
percentages of the antiproliferative synergism (figure 34). 
 
 
 
Figure 34: Role of autophagy in the antiproliferative synergism 
by GEM/cannabinoids in Panc1 cells. The analysis of 
antiproliferative synergism was made with  500 nM GEM and 
40 µM GW, 225 µM ACPA, or 40 µM SR1, in the absence or 
presence of 2,5 mM 3-MA or 10 µM CQ.  Values are the means 
of three independent experiments (±SD). p<0.001 
GEM/cannabinoids versus GEM/cannabinoids+3-MA or 
GEM/cannabinoids+CQ. 
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Altogether these data demonstrate that GEM further enhanced cannabinoid-induced 
autophagy by a ROS-mediated mechanism and that this event is required for 
GEM/cannabinoid synergism. 
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A kinetic analysis of the events involved in GEM/cannabinoid antiproliferative 
synergism shows that oxidative stress, ER stress, and autophagy occurred in different 
time-points after the beginning of the treatment. Indeed, Figure 35 shows that ROS 
were induced within 4 h, while the peak of Grp78 and LC3-II protein expression 
appeared at 8 h and 16 h, respectively, suggesting that ER stress could be a join 
mechanism between ROS induction and autophagic cell death.      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 35: Kinetic analysis of induction of ROS, Grp78, and LC3-II by 
GEM/cannabinoids in Panc1 cells. Cells were treated with 500 nM GEM 
and 40 µM GW, 225 µM ACPA, or 40 µM SR1 for the indicated time 
points. Values are the means of three independent experiments. 
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GEM and cannabinoids synergistically inhibit growth of human 
pancreatic adenocarcinoma cells in vivo 
 
For in vivo studies we chose SR1, in addition to GEM, on the basis of its clinical 
relevance [37]. PaCa44 cells were subcutaneously injected into female nude mice. 
After 1 week, intraperitoneal injection with PBS (solution vehicle), 25 mg/Kg GEM, 
or/and 0.28 mg/Kg SR1 were carried out twice a week for 4 weeks. The volume of 
the tumor in mice treated with the combination GEM+SR1 failed to enlarge, while it 
increased considerably in the control and, at a lower extent, after GEM or SR1 single 
treatments. The mice body masses did not change during the experiment, suggesting 
that the treatments did not produce any apparent toxicity (figure 36).  
 
Figure 36: Effect of GEM+SR1 on xenografts of PaCa44 cells in nude mice. 
PaCa44 cells were subcutaneously injected into female nude mice. After 1 week, i.p. 
injections with PBS (solution vehicle), GEM, or/and SR1 were carried out twice a 
week for 4 weeks. (A) Values are the means of mice tumour volume measured 3 
days after each injection. (B) Values are the means of mice body mass measured 3 
days after each injection. 
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At the end of the treatment period, the percentages of mean tumour mass reduction 
were 65%, 34%, or 92% in mice treated with GEM, SR1, or GEM+SR1, respectively 
(figure 37). 
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Figure 37: values of mean tumour mass reduction. 
Values are the means of mice tumour mass (±SD) 
measured after 8 injections. 
 
 
 
 
 
 
 
 
 
 
 
It is noteworthy that GEM+SR1 combination determined a quite total inhibition of 
tumour growth, as representatively shown in figure 38. 
 
GEM+SR1
1 cm 1 cm
1 cm1 cm
CTRL GEM
SR1
Figure 38: Representative photography of 
tumour masses derived from mice treated 
with the indicated drugs after 8 injections. 
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Discussion 
Discussion 
 
In the present study, we have demonstrated that the combination between the 
standard chemotherapeutic agent GEM and cannabinoids synergistically inhibits 
pancreatic adenocarcinoma cell growth by a ROS-dependent induction of autophagy. 
We used highly specific cannabinoid ligands of CB1 receptor (ACPA) and of CB2 
receptor (GW405833), and the clinically relevant CB1 ligand SR1. The latter has 
been described as a CB1 antagonist or inverse agonist [38], however, at high 
concentration it possesses an agonist activity [39]. Our results were in agreement 
with the last observation and additionally confirmed the dual and concentration-
dependent effect of SR1 on cell response (data not shown). It has been demonstrated 
that SR1, when applied at low concentration, increases the Ca2+ current [40], which 
is generally inhibited by a constitutive endocannabinoid-independent activity of CB1 
[41]. Because of its ability to block CB1, which controls food intake at central and 
peripheral level, SR1 has been adopted for the treatment of obesity and its metabolic 
complications, including type 2 diabetes, and atherosclerosis [42]. Besides those 
properties, SR1 has also been shown to exert antitumoral activity in rat thyroid 
cancer cell lines (KiMol) and in thyroid tumor xenografts [43]. Interestingly, it has 
recently been reported that SR1 has a stronger antiproliferative activity on the highly 
invasive metastatic MDA-MB-231 cells than in the less-invasive T47D and MCF-7 
cells [44]. In contrast to SR1, to our knowledge, the antitumor activity of ACPA and 
GW has never been reported before. Thus, our results show for the first time that 
SR1, ACPA, or GW are able to strongly inhibit pancreatic adenocarcinoma cell 
growth and to enhance the antiproliferative activity of GEM. To investigate if the 
synthetic cannabinoids SR1, ACPA, and GW were able to enhance cell growth 
inhibition induced by GEM we performed dose-dependent analyses of cell viability 
on six pancreatic adenocarcinoma cell lines: Panc1, PaCa3, PaCa44, T3M4, 
MiaPaCa2 and CFPAC1. These cell lines have a different sensitivity to GEM: Panc1, 
PaCa44 and PaCa3 are more resistant, while T3M4, MiaPaCa2 and T3M4 are more 
sensitive. We have demonstrated that the antiproliferative effect of the combination 
GEM/cannabinoids, as compared to single-drug treatments, was stronger in GEM-
resistant than in GEM-sensitive cell lines. By inverting the molar ratios of the 
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compounds between the two groups of cell lines, no significant alteration of the 
results was observed, indicating that the differential behaviour was not due to the 
specific experimental conditions tested. To evaluate whether cell growth inhibition 
by GEM/cannabinoids was synergistic, we analyzed the cell viability curves by using 
the dedicated software CalcuSyn: all combinations gave rise to a significant 
synergistic reduction of cell viability but the GEM resistant cell lines show a 
significant higher level of strong synergism compared to the GEM sensitive cell 
lines. Our data also demonstrate that low doses of GEM/cannabinoids for a treatment 
period of 24 h are able to significantly reduce pancreatic adenocarcinoma cell growth 
at least up to 6 days from the beginning of the treatment. This result may be 
clinically relevant suggesting the possibility to set up therapeutic protocols for 
pancreatic cancer with low doses of GEM/cannabinoids that could give reduced 
eventual side effects. Our data also show that cannabinoids were quite ineffective on 
normal fibroblasts and combined treatments with GEM did not further increase cell 
growth inhibition. These results are in agreement with the observations that 
cannabinoid receptors are overexpressed in cancer cells while are undetectable or 
expressed at low levels in normal cells [36] and that GEM is selectively active in 
cancer cells which generally show a higher growth rate as compared to normal 
counterpart. Analysis of ROS is a key element in this project, in fact our research 
group has reported that pancreatic adenocarcinoma cell growth is strongly inhibited 
by ROS-inducing compounds [12, 45]. Moreover, we have demonstrated that 
pancreatic adenocarcinoma cell growth inhibition by GEM is due, at least in part, to 
ROS induction and that cell lines with a lower basal level of ROS are more resistant 
to GEM compared to cells with higher ROS levels [11]. In fact, a 4h treatment with 
GEM/cannabinoids on Panc1 (a resistant cell lines) induces of about two fold ROS 
production compared to single treatments, while T3M4 (a sensitive cell line) shows 
no difference in ROS production. Similar results were obtained after 16 h or by 
inverting the molar ratios of the compounds between the two cell lines. Then, the 
further induction of ROS by the combined treatment is required for their synergism. 
This mechanism is supported by the observation that the radical scavenger NAC 
addition totally inhibits the synergistic antiproliferative effect induced by 
GEM/cannabinoids. These findings strongly support the idea that the increase of 
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ROS production may be a good strategy to overcome GEM resistance in the 
therapeutic management of pancreatic cancer.  
It has been previously described that cannabinoid receptor overexpression can 
potentiate cannabinoid antitumor effect [46]. Here, we report for the first time that 
GEM treatment determines CB1 and CB2 receptor gene induction, suggesting an 
involvement of this phenomenon on GEM/cannabinoid synergism. The regulation of 
CB1 and CB2 gene expression is currently poor studied. Recently, Borner et al. 
demonstrated that STAT6 mediates the induction of CB1 gene by IL-4 in T 
lymphocytes [47]. However, it has never been reported that GEM treatment can 
activate STAT6, strongly suggesting that CB1 and CB2 gene induction by GEM 
occurs by a different mechanism. Since NF-κB is one of the most important 
transcription factors induced by GEM [48], we analyzed CB gene induction by GEM 
in the presence of NF-κB inhibitors, such as MG132, a proteasome inhibitor that 
inhibits NF-κB activation  by preventing IκB degradation, BAY, that is an inhibitor 
of cytokine-induced IκB-α phosphorylation, PDTC, an antioxidant which inhibit the 
activation of NF-κB. Interestingly, we show that CB induction by GEM is totally 
prevented by these inhibitors and that IL-1, a known inducer of NF-κB, is able to 
induce CB genes. Similar results were obtained using TNF-α. Since NF-κB induction 
is described to be mediated by oxidative stress [49], we analyzed CB expression after 
NAC addition. Our data show that it fails to prevent NF-κB induction indicating that 
GEM induces CB gene with a ROS-independent mechanism. The molecular 
mechanism at the basis of NF-κB induction by GEM is still unknown and its 
clarification needs further investigations. Interestingly, the addition of the histone 
deacetylase inhibitor TSA strongly enhances the NF-κB-dependent CB gene 
expression induced by GEM. This effect could be due to histone hyperacetylation of 
the regulatory region of CB gene enhancing binding of NF-κB. An alternative 
hypothesis is that TSA is able to induce NF-κB acetylation promoting its 
transcriptional activation, DNA binding affinity, I-κBα assembly or subcellular 
localization, as previously described [50]. Our previous papers reported that 
GEM/TSA determined a strong synergistic inhibition of pancreatic cancer cell 
growth, both in vitro and in vivo [11]. The present data strongly indicate that 
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GEM/cannabinoid effect could be further potentiated by addition of TSA, suggesting 
that this triplicate therapy could be an efficient strategy to inhibit pancreatic cancer 
cell growth. We have also demonstrated that CB mRNAs induction by GEM was 
transcriptionally regulated, as indicated by its complete inhibition following 
actinomycin D treatment. 
The involvement of ER stress induction in cannabinoid antiproliferative effect has 
been already described [36]. According with this observation, we report that the 
cannabinoids ACPA, GW, and SR1 activate: i) the splicing of XBP-1, a transcription 
factor that regulates the expression of genes important in the cellular stress response; 
ii) the gene expression of Grp78, a molecular chaperone located in the lumen of the 
endoplasmic reticulum that is an abundant protein under all growth conditions, but its 
synthesis is markedly induced under conditions that lead to the accumulation of 
unfolded polypeptides in the ER; iii) the gene expression of CHOP, which is the 
molecular switch inducing apoptotic or autophagic cell death signals [51, 52]. 
Interestingly, we show that all three ER stress-related genes induced by 
cannabinoids, including CHOP, are further enhanced by GEM, supporting their 
involvement in GEM/cannabinoid antiproliferative synergism.  
To assess how the combination GEM/cannabinoids are able to synergistically inhibit 
the pancreatic adenocarcinoma cells proliferation, we analyzed the cell cycle 
perturbation, apoptosis, and autophagy in the resistant cell line Panc1. It has been 
reported that THC induces caspase activation in pancreatic tumor cells [36]. In 
contrast, our data demonstrate that SR1, ACPA, or GW do not induce apoptotic cell 
death, although they induce cell cycle arrest at the G1 phase. The discrepancy 
between our results and those of Carracedo et al. [36] may rely on the nature of THC, 
which is a non-specific cannabinoid receptor agonist, and needs further 
investigations to be explained. Moreover, our results demonstrate that GEM-induced 
apoptosis is partially, but significantly prevented by cannabinoids. Since it has been 
reported that autophagy generally precedes apoptosis [53], one possible explanation 
may be that the stimulation of autophagy by SR1, ACPA, or GW or by their 
combination with GEM is so elevated to inhibit the development of the apoptotic cell 
death program. On the other hand, in line with the recent discovery that THC action 
induces autophagy-mediated cell death in human glioma cells [17], we describe for 
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the first time that GW, ACPA, and SR1 are able to induce autophagy in pancreatic 
cancer cells and that GEM  strongly enhances the effect of all three cannabinoids 
analyzed. In fact, we have demonstrated that the protein LC3-II and the formation of 
autolysosomes increase following treatment with GEM and/or GW, ACPA, SR1. In 
addition, we demonstrate that the induction of autophagy by GEM/cannabinoids is 
significantly inhibited by NAC, thus almost completely preventing the 
antiproliferative synergism. Similar results are obtained with the lysosomal 
hydrolysis inhibitor CQ, which determines an accumulation of autophagosome 
vesicles containing LC3-II protein and 3-MA, an inhibitor of the class III 
phosphatidylinositol 3-kinase (class III PI3K) complex involved in initial 
autophagosome formation.  
Our kinetic studies reveal that ROS induction by drug combinations precedes the 
activation of the ER stress marker Grp78, which, in turn, precedes the autophagy 
marker LC3-II induction. The observation that LC3-II increase is prevented by NAC 
and that ROS can induce ER stress [54, 55] strongly support the hypothesis that 
oxidative stress, ER stress, and autophagic cell death are sequential events.  
Our results demonstrate that GEM strongly potentiates the pathways involved in 
pancreatic adenocarcinoma cell death by cannabinoids rather than vice versa. To 
support this concept, we report that GEM is able to induce both CB1 and CB2 genes, 
thus stimulating the cannabinoid transduction pathway. In addition, previous studies 
described that GEM is able to stimulate sphingomyelinase or inhibit neutral 
ceramidase enhancing intracellular ceramide levels [56]. The regulation of ceramide 
metabolism by GEM, coupled with the observation that the cannabinoid transduction 
pathway involves ceramide production [57], which in turn is able to induce oxidative 
stress [58], may be at the basis of the ROS-dependent synergistic autophagic cell 
death by GEM/cannabinoid combination. In line with our results, in fact, it has been 
reported that the addition of sphingomyelin, a ceramide precursor, to GEM is able to 
synergistically inhibit pancreatic cancer cell growth [59].   
For in vivo studies we chose SR1, in addition to GEM, on the basis of its clinical 
relevance [37]. Our in vivo experiments show that intraperitoneal injections of the 
combination GEM/SR1 into nude mice bearing a subcutaneous mass of human 
pancreatic adenocarcinoma cells quite completely inhibit tumour growth. No 
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apparent form of toxicity in vivo, such as mice death, body mass variations, or other 
apparent toxicity-related features, was observed in mice treated with the combination 
GEM/SR1.  
In conclusion, data in this thesis provide the first evidence that the combination 
GEM/cannabinoids exerts a strong synergistic antiproliferative effect on pancreatic 
adenocarcinoma GEM-resistant cell lines by ROS-dependent mechanisms, while it is 
scarcely toxic towards normal cells. Furthermore, in vivo studies strongly boost the 
addition of cannabinoids to GEM in designing new therapeutic strategies for 
pancreatic cancer treatment. 
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